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Virtual screening (VS) can provide valuable contributions in hit and lead 
compound discovery. Numerous software tools have been developed for this 
purpose.  However, the insufficient coverage of compound diversity, high 
false positive, high false negative prediction and lower speed of screening 
compound libraries are also required to address in the development of virtual 
screening methods. In this work, training-sets of diverse inactive compounds 
are used to improve the performance of Support vector machine (SVM) virtual 
screening tools. In retrospective database screening of active compounds of 
single mechanism (HIV protease inhibitors, DHFR inhibitors, dopamine 
antagonists) and multiple mechanisms (CNS active agents) from large libraries 
of 2.986 million compounds, the yields, hit-rates, and enrichment factors of 
our SVM models are  compared to those of structure-based VS and other 
ligand-based VS tools in screening libraries of ≥1 million compounds. The 
hit-rates are comparable and the enrichment factors are substantially better 
than the best results of other VS tools. SVM appears to be potentially useful 
for facilitating lead discovery in VS of large compound libraries. 
 
Virtual screening performance of SVM depends on the diversity of training 
active and inactive compounds. We also evaluated the performance of SVM 
trained by sparsely distributed actives in six MDDR biological target classes 
composed of high number of known actives of high, intermediate, and low 
structural diversity. The results show SVM has substantial capability in 




 c-Src and VEGFR-2 are two important kinases that play various roles in 
tumour progression, invasion, metastasis, angiogenesis and survival. The 
successes of their inhibitors and the encountered problems have led to further 
efforts for discovering new inhibitors for c-Src and VEGFR-2. We applied our 
developed SVM based virtual screening tools for searching c-Src and VEGFR-
2 inhibitors from large compound libraries. SVM models showed around 60% 
accuracy for independent testing sets and >99.9% accuracy for non-inhibitors 
(very low false hit-rate) that is favorable for selecting potential leads to further 
study in wet-lab experiment. 
 
Multi-target agents have been increasingly explored for enhancing therapeutic 
efficacies and improving safety and resistance profiles by selectively 
modulating the elements of these counter-target and toxicity activities. In the 
final part of my thesis, combinatorial support vector machines (C-SVMs), 
virtual screening tools for searching multi-target agents are developed based 
on our previous high performance SVM based virtual screening tools. C-
SVMs models were tested for searching dual-inhibitors of 11 combinations of 
9 anticancer kinase targets (EGFR, VEGFR, PDGFR, Src, FGFR, Lck, CDK1, 
CDK2, GSK3). Moreover, C-SVMs were compared to other VS methods 
DOCK Blaster, kNN and PNN against the same sets of kinase inhibitors and 
1.02M Zinc clean-leads dataset. C-SVMs produced comparable dual-inhibitor 
yields, slightly better false-hit rates for kinase inhibitors, and significantly 
lower false-hit rates for the Zinc clean-leads dataset. 
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Chapter 1 Introduction 
The discovery of novel chemical entities (NCEs) in the pharmaceutical 
industry is becoming increasingly difficult, costly and time-consuming. Many 
approaches have been suggested to increase the cost-effectiveness of 
discovery programmes, one of them being the use of virtual screening methods 
to complement the more traditional chemical and biological approaches. 
Presently, a variety of computational virtual screening tools are being 
developed and refined to effectively employ fast screening methods to yield 
potent lead hits such as docking, quantitative structure activity relationship 
(QSAR) and machine learning methods etc. However, virtual screening also 
faces several fundamental challenges. It can be regarded as less accurate, 
since speed and the possibility to capture most (but not necessarily all) 
potentially positives are its key attributes. The insufficient coverage of 
compound diversity, high false positive, high false negative prediction and 
lower speed of screening compound libraries are also required to address in 
the development of virtual screening method. This work on “high performance 
computational virtual screening tools: development and application to the 
discovery of kinase inhibitors” is one of such kind of strategies to improve the 
screening speed and the prediction accuracy and decrease the false hit rate.  
 
The following sections will describe an overview of virtual screening in drug 
discovery (Section 1.1), machine learning methods in virtual screening 
(Section 1.2) and discuss the important role of kinase inhibitors in cancer 
treatment (Section 1.3) and in-silico approaches to multi-target drug 
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discovery (Section 1.4). In addition, the objectives and outline of this project 
(Section 1.5) will be introduced. 
1.1 Virtual screening in drug discovery 
In current drug discovery, lead compounds of high quality and structural 
diversity are keys to the successful development of the drug candidates. 
During the last 10 to 15 years, High throughput screening (HTS) of 
proprietary compound collections at pharmaceutical companies has 
represented the most important source of leads in the industry. However, the 
use of HTS is very expensive and companies need to purchase the synthesized 
compounds to be screened (if available at all). Moreover, these physically 
existing compounds (in-house libraries) represent only a tiny fraction of the 
drug-like chemical space. In more recent years, virtual screening (VS) has 
complemented the experimental identification of bioactive compounds. Virtual 
screening offers many possibilities for new structures beyond those found in 
in-house libraries. The term 'virtual screening' was first used in 1997, and 
relates to the search for compounds with a defined biological activity using 
computational models1. During the last decade, a huge number of different 
virtual screening methods have been reported and used to search for novel 
bioactive compounds for many targets. Like HTS, VS searches large libraries 
of potentially bioactive molecules for hits. Unlike HTS, there is no need for 
physically existing compounds, which is a key advantage of VS. Another 
advantage of VS comes from the exploration of the chemical space outside the 
in-house compound pool. The typical screening collection of a large 
pharmaceutical company is of the order of a few million compounds at most. 
This is a tiny fraction of the huge chemical space2,3, which is many orders of 
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magnitude larger than this, even if only drug-like compounds are considered4. 
Of the order of 10 million compounds are commercially available, which are 
an additional source of potential leads that can be exploited with the VS 
approach. Another source of accessible compounds is virtual combinatorial 
libraries. The chemical space accessible through virtual combinatorial libraries 
is at least 1 million-fold larger than that available from in-house pools and 
external vendor compounds, respectively, and adds a new dimension to the VS 
search space (Figure 1-1).  
 
 
Figure 1-1 Typical numbers of compounds available in the chemical space. 
 
Virtual screening methods are often divided into structure-based virtual 
screening (SBVS) and ligand-based virtual screening (LBVS)  depending on 
what is already known about a target and its ligands5. Structure-based virtual 
screening involves docking of candidate ligands into a protein target followed 
by applying a scoring function to estimate the likelihood that the ligand will 
bind to the protein with high affinity6,7. LBVS methods include 
pharmacophore methods8 and chemical similarity analysis methods9. Figure 
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Figure 1-2 General procedure used in SBVS and LBVS (adopted from Rafael 




1.1.1 Structure-based virtual screening  
When 3D protein target structure information, derived either from 
experimental data (X-ray or NMR spectroscopy) or from homology modeling, 
is available, the most frequently used VS method is docking. Binding modes 
for each ligand can be predicted in silico, together with numerical assessment 
(score) of the interaction energy between the ligand and the protein. Most 
docking algorithms and scoring functions are tuned towards high throughput, 
which requires a compromise between the speed and accuracy of binding 
mode and energy prediction. The major challenges in scoring functions are 
how to account for the solvent effect and how to accurately account for 
entropic effect. Now desolvation and entropy contributions of both ligand and 
protein are included only in an approximate way. To date, more than 60 
docking programs and 30 scoring functions have been reported. Both docking 
programs and scoring functions have been evaluated and reviewed 
extensively11,12. Most researchers agree that there is currently no single 
docking program that outperforms all others with regard to either docking 
accuracy or hit enrichment. The hit enrichment is defined as the fraction of 
true active compounds in, for example, the upper 1% of the ranked VS hit list 
compared with the average fraction of active compounds in the search space. 
The performance of a docking program is difficult to assess in advance, and 
depends on the nature of the target11-13. Despite all optimization efforts, the 
currently available scoring functions do not provide reliable estimates of free 
binding energies, and are not able to rank-order compounds according to 
affinity12,14. The published comparisons of docking programs have been 




1.1.2 Ligand-based virtual screening  
Ligand-based VS begins with the use of one or more active compounds as 
templates, and no details about the target are needed. In general, LBVS 
methods depend on the application of computational descriptors of molecular 
structure, properties, or pharmacophore features and analyze relationships 
between active and database or test compounds in however defined chemical 
descriptor spaces. It is computationally efficient and can rapidly search very 
large databases. As a result, it is often used to sequentially filter large 
compound sets before more complex tools are applied. Myriads of different 
methods have been reported, and there are literally thousands of different 
descriptors, which are derived from the 2D or 3D distribution of atomic 
properties in compounds, or from the presence or absence of specific structural 
elements. Many methods exist for the comparison of the similarity of 
compounds based on these descriptors. In ligand-based VS, shape comparison 
is frequently used18, and pharmacophore searches are also a long-established 
technique8,19. Other methods use molecular fields to define the similarity of 
structures20,21. If large sets of active and inactive compounds are known, 
machine learning techniques, such as artificial neural nets, decision trees, 
support vector machines or Bayesian classifiers, can be used to train models 
that distinguish active from inactive compounds based on their specific 
structural features. For a comprehensive overview of ligand-based VS the 
reader is referred to a number of reviews22,23. 
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1.2 Machine learning in virtual screening 
Machine learning methods have been explored as an alternative virtual 
screening method. It utilize nonlinear supervised learning methods to develop 
statistical models that map physicochemical properties (molecular descriptors) 
with their activity classes, so they are more capable of predicting a more 
diverse spectrum of compounds and more complex structure-activity 
relationships than structure-based virtual screening methods and other ligand-
based virtual screening methods such as QSAR, pharmacophore, and 
clustering methods24-31. This capability arises because machine learning 
methods are capable of generating complex nonlinear mappings from 
molecular descriptors to activity classes without restriction on structural 
frameworks, and without requiring prior knowledge of relevant molecular 
descriptors and functional form of structure-activity relationships32-36. 
Moreover, machine learning methods can overcome several problems that 
have impeded progress in the application of structure-based virtual screening 
and other ligand-based virtual screening tools33,37. These problems include the 
vastness and sparse nature of searched chemical space, limited availability of 
target structures (only 15% of known proteins have known 3D structures); 
limited diversity biased by training molecules, complexity and flexibility of 
target structures, and difficulties in computing binding affinity and solvation 
effects.  
 
The reported performance of machine learning methods in screening 
pharmacodynamically active compounds from libraries of >25,000 compounds 
is summarized in Table 1-1. The screening tasks of these reported studies38-45 
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are primarily focused on the prediction of compounds that inhibit, antagonize, 
block, agonize, or activate specific therapeutic target protein. Machine 
learning methods have been found to show generally good performances. In 
the majority of the reported studies, the yields, hit rates, and enrichment 
factors of machine learning methods are in the range of 50%~94%, 10%~98%, 
and 30~108 respectively. 
 
For tentative comparison of the performance of machine learning methods 
with other virtual screening methods, the reported performances of structure-
based VS methods and two classes of ligand-based VS methods, 
pharmacophore and clustering, are summarized in Table 2, Table 3 and Table 
4 respectively. The yields, hit rates, and enrichment factors of the majority of 
the reported studies by other methods shown in Table 1-2, Table 1-3 and 
Table 1-4 are in the range of 7%~95%, 1%~32%, and 5~1189 for structure-
based, 11%~76%, ~0.33%, and 3~41 for pharmacophore, and 20%~63%, 
2%~10%, and 6~54 for clustering methods respectively. Therefore, the 
general performance of machine learning methods appears to be comparable to 
or in some cases better than the reported performances of the VS studies by 
using structure-based, pharmacophore and clustering methods. However, we 
can see from the Table 1-2, Table 1-3, Table 1-4, in screening extremely-
large libraries, the reported yields, hit-rates and enrichment factors of machine 
learning VS tools are in the range of 55%~81%, 0.2%~0.7% and 110~795 
respectively, compared to those of 62%~95%, 0.65%~35% and 20~1,200 by 
structure-based VS tools In screening libraries of ~98,000 compounds, the 
reported hit-rates of some machine learning VS tools are comparable to those 
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of structure-based VS tools, but their enrichment factors are substantially 
smaller. Therefore, while exhibiting equally good yield, in screening 
extremely-large (≥1 million) and large (130,000~400,000) libraries, the 
currently developed machine learning VS tools appear to show lower hit-rates 
and, in some cases, lower enrichment factors than the best performing 
structure-based VS tools.  
 
Two approaches have been explored to improve hit-rates and enrichment 
factors. One is the selection of top-ranked hits, which has been extensively 
used in ligand-based46-51 and structure-based 52-57 VS tools. The other is the 
elimination of unlikely hits at the pre-screening stage by using such filters as 
Lipinski’s rule of five58 for drug-like compounds, identification of specific 
chemical groups or interaction patterns52,53,59,60, and pharmacophore 
recognition54. These two methods are effective to improve hit-rates and 
enrichment factors but they are just supplemental methods combined with 
virtual screening methods. Higher performance virtual screening methods are 
required. The performance of machine learning VS tools in screening large 
libraries can be further improved by using training sets of more diverse 
spectrum of compounds to develop more optimally performing machine 
learning VS tools.  These tools have been generated by using two-tier 
supervised classification machine learning methods36,46-49,61-63, which require 
training sets of diverse spectrum of active and inactive compounds.  
 
Machine learning methods have shown promising capability in virtual 
screening of compounds of diverse ranges of structures for identifying 
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compounds of a wide variety of pharmacodynamic and other properties. In 
virtual screening of large libraries, these methods have been found to be 
capable of achieving comparable performance to other structure-based and 
ligand-based VS methods. By using training sets of more diverse spectrum of 
inactive compounds, the hit-rates and enrichment factors of machine learning 
VS tools can be substantially improved to the level comparable to and in some 
cases higher than those of the best performing structure-based and ligand-




Table 1-1 Performance of machine learning methods in virtual screening test for identifying inhibitors, agonists and substrates of 









































2.5M 22 SVM 49 Molecular 
fingerprints
94/200K 2,500 0.1% 18 81% 0.7% 795 










102,514 536 BKD 48,51 Extended 
connectivity 
fingerprints 




98,435 536 CKD 36 Pipeline pilot 100/4000 984 1% 232 43.4% 23.7% 43.1 
ECFP4 100/4000 984 1% 365 68.1% 37.2% 67.7 
SVM-
RBF 36  
Pipeline pilot 100/4000 984 1% 240 44.7% 24.4% 44.5 
Thrombin 
inhibitors 
2.5M 46 SVM 49 Molecular 
fingerprints 




102,514 703 BKD 48,51 Extended 
connectivity 
fingerprints 




98,435 703 CKD 36  Pipeline pilot 100/4000 984 1% 435 61.9% 44.4% 61.7 
ECFP4 100/4000 984 1% 603 85.8% 61.5% 85.5 
SVM-
RBF 36
Pipeline pilot 100/4000 984 1% 381 54.2% 38.9% 54.0 
Protease 
inhibitors 
171,726 118 SVM 47 Extended 
connectivity 
fingerprints 











171,560 128 SVM 47 Extended 
connectivity 
fingerprints 














102,514 652 BKD 48,51 Extended 
connectivity 
fingerprints 




98,435 852 CKD 36 Pipeline pilot 100/4000 984 1% 480 56.4% 49.0% 56.3 
ECFP4 100/4000 984 1% 680 79.8% 69.4% 79.8 
SVM-
RBF 36 
Pipeline pilot 100/4000 984 1% 529 62.1% 54.0% 62.1 
5HT1A 
antagonists 
102,514 727 BKD 48,51 Extended 
connectivity 
fingerprints 




98,435 727 CKD 36 Pipeline pilot 100/4000 984 1% 268 36.9% 27.3% 36.9
ECFP4 100/4000 984 1% 426 58.6% 43.5% 58.7 
SVM-
RBF 36 
Pipeline pilot 100/4000 984 1% 319 43.9% 32.6% 44.0 
5HT reuptake 
inhibitors 
102,514 259 BKD 48,51 Extended 
connectivity 
fingerprints 
100/400 5125 5% 65 25% 1.2% 4.7 
 
98,435 259 CKD 36  Pipeline pilot 100/4000 984 1% 131 50.7% 13.4% 51.5 
ECFP4 100/4000 984 1% 194 75.6% 19.7% 75.9 
SVM-
RBF 36  
Pipeline pilot 100/4000 984 1% 137 52.9% 14.0% 53.8 
D2 
antagonists 
102,514 295 BKD 48,51 Extended 
connectivity 
fingerprints 




98,435 295 CKD 36 Pipeline pilot 100/4000 984 1% 132 44.7% 13.5% 44.9 
ECFP4 100/4000 984 1% 219 74.4% 22.4% 74.7 
SVM-
RBF 36 
Pipeline pilot 100/4000 984 1% 137 46.4% 14.0% 53.8 
Rennin 
inhibitors 
102,514 1030 BKD 48,51 Extended 
connectivity 
fingerprints 




98,435 1030 CKD 36  Pipeline pilot 100/4000 984 1% 842 81.8% 86.0% 81.9 
ECFP4 100/4000 984 1% 960 93.2% 98.0% 93.3 
SVM-
RBF 36




102,514 843 BKD 48,51 Extended 
connectivity 
fingerprints 






98,435 843 CKD 36  Pipeline pilot 100/4000 984 1% 393 46.6% 40.1% 46.6 
ECFP4 100/4000 984 1% 593 70.4% 60.6% 70.4 
SVM-
RBF 36 
Pipeline pilot 100/4000 984 1% 384 45.6% 39.2% 45.6 
Substance P 
antagonists 
102,514 1146 BKD 48,51 Extended 
connectivity 
fingerprints 




98,435 1146 CKD 36 Pipeline pilot 100/4000 984 1% 705 61.5% 71.9% 61.5 
ECFP4 100/4000 984 1% 942 82.2% 96.1% 82.2 
SVM-
RBF 36 
Pipeline pilot 100/4000 984 1% 509 44.4% 51.9% 44.4 
HIV protease 
inhibitors 
102,514 650 BKD 48,51 Extended 
connectivity 
fingerprints 




98,435 650 CKD 36 Pipeline pilot 100/4000 984 1% 436 67.1% 44.5% 67.4 
ECFP4 100/4000 984 1% 574 88.3% 58.6% 88.7 
SVM-
RBF 36
Pipeline pilot 100/4000 984 1% 355 54.6% 36.2% 54.9 
Protein kinase 
C inhibitors 
102,514 353 BKD 48,51 Extended 
connectivity 
fingerprints 




98,435 353 CKD 36  Pipeline pilot 100/4000 984 1% 238 67.3% 24.2% 67.3 
ECFP4 100/4000 984 1% 291 82.5% 29.7% 82.5 
SVM-
RBF 36 
Pipeline pilot 100/4000 984 1% 206 58.3% 21.0% 58.3 
MAO 
inhibitors 










98,435 748 CKD 36 Pipeline pilot 100/4000 984 1% 467 62.4% 47.4% 62.4




98,435 1211 CKD 36 Pipeline pilot 100/4000 984 1% 604 49.9% 61.4% 49.9 




98,435 277 CKD 36 Pipeline pilot 100/4000 984 1% 192 69.3% 19.5% 69.7
ECFP4 100/4000 984 1% 244 88.2% 27.3% 97.6 









98,435 419 CKD 36 Pipeline pilot 100/4000 984 1% 238 56.9% 24.2% 56.3 
ECFP4 100/4000 984 1% 337 80.4% 34.2% 79.6 
Aromatase 
inhibitors 
98,435 413 CKD 36 Pipeline pilot 100/4000 984 1% 284 68.7% 28.8% 68.6 
ECFP4 100/4000 984 1% 389 94.1% 39.5% 94.0 
Phospholipase 
A2 inhibitors 
98,435 604 CKD 36 Pipeline pilot 100/4000 984 1% 297 49.2% 30.2% 49.5 
ECFP4 100/4000 984 1% 447 74.0% 45.4% 74.5 
CDK2 
inhibitors 











































125/5035 506 2% 20 80% 3.9% 39.5 
 
BKD – binary kernel discrimination; CKD – Continuous kernel discrimination; DS – decision tree; LMNB – laplacian modified naive Bayesian; SVM – 
support vector machine; DRAGON – (an application for the calculation of molecular descriptors); AR – androgen receptor; PDE 5 – phosphodiesterase 





Table 1-2 Performance of docking methods in virtual screening test for identifying inhibitors, agonists and substrates of proteins 
of pharmaceutical relevance. The relevant literature references are given in the method column. 
 































Factor Xa inhibitors 2M 630 AUTODOCK 
+ pre-docking 
RO5 and EA 
screen 65 
60,000 Binding 
energy <   
-10.5 
kcal/mol 
60,000 3% 392 62% 0.65% 20 
COX2 inhibitors 1.2M 355 DOCK+ pre-
docking 
chemical group 
screen 52  
13,711 DOCK 
scores <    
-35 














400K >4 DOCK4 + H-
bond and hinge 
segment screen 
59  
<400K N/A 35 0.0087% 4 N/A 11.4% N/A 
Thyroid hormone 
receptor antagonists 
250K >14 ICM VLS 
module 













14 N/A 18.7% N/A 







889 0.38% 127 N/A 14.3% N/A 




<141K Top-2% <2820 <2.5% 8 80% <0.28% 39.4 
BCL-2 inhibitors 206,876 >1 DOCK3.5 + 
non-peptidic 










<141K Top-5% <7050 <5% 1 20% <0.014% 4.6 




<141K Top-5% <7050 <5% 4 28.6% <0.056% 5.7 













22,950 Top-300 300 0.21% 38 N/A N/A N/A 




<141K Top-2% <2820 <2.5% 3 30% <0.11% 15.5 
133.8K 760 FlexX + 
Similarity 69 
<133.8K Top-1% 1338 1% 231 29.3% 17.3% 30.5 
DHFR inhibitors 135K 165 DOCK3.5.54 





1350 1% 47 25% 3.4% 27.8 
DOCK3.5.54 















1255 0.74% 3 0.8% 0.24% ~1 
















540 0.4% 49 26.5% 9.1% 66.4 
Phospholipase C 
inhibitors 





1230 0.9% 5 20% 0.4% 21.6 
Adenosine kinase 
inhibitors 
135K 356 DOCK3.5.54 





4500 3.3% 10 2.8% 0.22% ~1 
DOCK3.5.54 





4500 3.3% 5 1.4% 0.11% <1 
133.8K 59 FlexX + 
Similarity 69 
<133.8K Top-1% 1338 1% 13 22% 0.97% 22.0 
Acetylcholinesterase 
inhibitors  
135K 637 DOCK3.5.54 





770 0.57% 49 7.7% 6.4% 13.6 
DOCK3.5.54 





375 0.28% 25 3.9% 6.7% 14.2 
HMG-CoA 
reductase inhibitors 
133.8K 1016 FlexX + 
Similarity 69 




Table 1-3 Performance of pharmacophore methods in virtual screening test for identifying inhibitors, agonists and substrates of 




Compounds screened Method and 
reference of 
reported study 



























3.8M 55 Structure-based 
pharmacophore 71 













Table 1-4 Performance of clustering methods in virtual screening test for identifying inhibitors, agonists and substrates of 




Compounds screened Method and reference 
of reported study 



























NIPALSTREE 29 8174 2.4% 188 38.4% 2.3% 16.2 
Hierachical k-means + 
NIPALSTREE 
disjunction 29 
12240 3.6% 306 62.4% 2.5% 17.6 
Hierachical k-means + 
NIPALSTREE 
conjunction 29 
1662 0.48% 128 26.1% 7.7% 54 
COX 
inhibitors 
344.5K 1556 Hierachical k-means 29 15322 4.4% 761 48.9% 5.0% 11 
NIPALSTREE 29 22321 6.5% 625 40.2% 2.8% 6.16 
Hierachical k-means + 
NIPALSTREE 
disjunction 29 
33793 9.8% 980 63.0% 2.9% 6.42 
Hierachical k-means + 
NIPALSTREE 
conjunction 29 
3980 1.2% 406 26.1% 10.2% 22.6 
Adrenoceptor 
ligand 
344.5K 542 Hierachical k-means 29 21285 6.2% 298 55.0% 1.4% 8.99 
NIPALSTREE 29 28125 8.2% 270 49.8% 0.96% 6.14 
Hierachical k-means + 
NIPALSTREE 
disjunction 29 
42365 12.3% 394 72.7% 0.93% 5.93 
Hierachical k-means + 
NIPALSTREE 
conjunction 29 






344.5K 91 Hierachical k-means 29 3750 1.1% 27 29.7% 0.72% 27..3 
NIPALSTREE 29 3469 1.0% 17 18.7% 0.49% 18.7 
Hierachical k-means + 
NIPALSTREE 
disjunction 29 
7317 2.1% 30 33.0% 0.41% 15.6 
Hierachical k-means + 
NIPALSTREE 
conjunction 29 




344.5K 478 Hierachical k-means 29 10000 2.9% 110 23% 1.1% 7.97 
NIPALSTREE 29 17143 5.0% 84 17.6% 0.49% 3.51 
Hierachical k-means + 
NIPALSTREE 
disjunction 29 
24265 7.0% 165 34.5% 0.68% 4.86 
Hierachical k-means + 
NIPALSTREE 
conjunction 29 




1.3 Protein kinase inhibitors in cancer treatment 
There are some 518 protein kinases that share a catalytic domain highly 
conserved in sequence and structure in the human genome. The kinase family 
is one of the largest target families and its key function in signal transduction 
for all organisms makes it a very attractive target class for therapeutic 
interventions in many disease states such as cancer, diabetes, inflammation, 
and arthritis. Protein kinases play important roles in regulating most cellular 
functions such as proliferation/cell cycle, cell metabolism, survival/apoptosis, 
DNA damage repair, cell motility, response to the microenvironment, so they 
are often themselves oncogenes. Kinases such as c-Src, c-Abl, mitogen 
activated protein (MAP) kinase, phosphotidylinositol-3-kinase (PI3K) AKT, 
and the epidermal growth factor (EGF) receptor are commonly activated in 
cancer cells, and are known to contribute to tumorigenesis72,73. Small molecule 
kinase inhibitors have been designed to inhibit the enzyme's adenosine 
triphosphate (ATP) binding site for cancer treatment74. There are currently 
over 70 reported small molecule kinase inhibitors at various stages of clinical 
trials in oncology (www.clinicaltrials.gov) which emphasises the potential 
importance in targeting protein kinases for treating human malignancies. The 
advent of kinase targeted therapy for the treatment of human cancer offers a 
potential therapy to improve both patient survival and quality of life during 
treatment75. 
 
Kinase inhibitors designed to bind the catalytic ATP-binding site can have 
broad specificity because of kinases’ high conserved sequence and structure. 
Imatinib (Gleevec, Novartis) is a highly successful cancer drug due to its 
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activity as an inhibitor of the Abelson cytoplasmic tyrosine kinase (Abl), 
which is constitutively active in a majority of patients with chronic 
myelogenous leukemia (FDA-approved in May 2001). Imatinib also inhibit c-
Kit and the platelet-derived growth factor (PDGF) receptor tyrosine kinases. 
So it can be used to treat gastrointestinal stromal and other types of tumors 
associated with activation of these signaling molecules. Cancer cells use 
multiple pathways to promote their own survival and proliferation, 
combination therapies (of multiple targeted therapeutics, or of targeted drugs 
plus chemotherapy) are likely to be required to completely eradicate a tumor 
and prevent resistance or relapse. Due to kinases’ broad specificity, it is 
possible to design multi-target kinase inhibitors for achieving enhanced 
therapeutic efficacies through controlling multiple pathways in cancer network. 
However, just because of this broad specificity, many kinase inhibitors have 
“off-target” effect in modulating signaling pathway. It is also necessary to 
design more specific kinase inhibitors for cancer treatment.  
1.4 In-Silico approaches to multi-target drug discovery 
Therapeutic agents directed at an individual target frequently show reduced 
efficacies, undesired safety profiles and drug resistances due to network 
robustness76, redundancy77, crosstalk78, compensatory and neutralizing 
actions79, anti-target and counter-target activities80, and on-target and off-
target toxicities81. Multi-target agents directed at selected multiple targets have 
been increasingly explored76,82 for achieving enhanced therapeutic efficacies, 
improved safety profiles, and reduced resistance activities by simultaneously 
modulating the activity of a primary therapeutic target and the counteractive 
elements and resistance activities83 while limiting un-wanted cross-reactivities 
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via optimization of target selectivity84. Examples of clinically successful 
multi-target drugs are anticancer kinase inhibitors sunitinib against PDGFR 
and VEGFR, dasatinib against Abl and Src, and lapatinib against EGFR and 
HER285,86. These multi-target anticancer agents inhibit a primary therapeutic 
target that promote tumor growth in specific cancer patient group and block 
the alternative signalling or escape mechanism79,87,88.  
 
In-silico methods have been widely explored for facilitating lead discovery 
against individual targets37,89,90. In particular, molecular docking91, 
pharmacophore92, structure-activity relationship (SAR) and quantitative 
structure activity relationship (QSAR)93, machine learning94, and combination 
methods95 have been extensively used for searching and designing active 
compounds against individual targets. Some of these methods have recently 
been explored for searching and designing multi-target agents. Figure 1-3, 
Figure 1-4, Figure 1-5, and Figure 1-6 outline the strategies of using 
molecular docking, combined molecular docking and pharmacophore, 
framework combination, and fragment-based approaches for multi-target drug 
discovery using dual-inhibitor discovery as examples. These methods are 
classified into combinatorial approaches and fragment–based approaches. 
Combinatorial approaches (Figure 1-3 and Figure 1-4) straightforwardly 
conduct parallel search against each individual targets to find virtual hits that 
simultaneously interact with multiple targets. Combinatorial approaches are 
practically useful if the retrieval rates against individual targets are sufficiently 
high and the false-hit rates are sufficiently low. High retrieval rates 
compensate for the reduced collective retrieval rates (if the retrieval rate 
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against individual target is 50%~70%, the collective retrieval rate for multi-
target agents against two targets may be statistically reduced to 25%~49%). 
Low false-hit rates are needed for high enrichment in searching multi-target 
agents that are significantly fewer in numbers and more sparsely distributed in 










Figure 1-4 Combined pharmacophore and molecular docking strategy of 
















Fragment-based approaches (Figure 1-5 and Figure 1-6) combine multiple 
elements of structural frameworks or multiple fragments that bind to each 
individual target to design compounds that bind to multiple targets, which 
have been introduced as tools for the design of multi-target agents96. In one 
approach, the structure-activity relationships against individual targets are 
analyzed to find molecular fragments and essential binding features which are 
either combined or incorporated into active agents against selected multiple 
targets96. Fragment combination often results in larger and more complex non-
drug like molecules. Drug-like features may be retained if the degree of 
framework overlap is maximized and the size of the selected fragments is 
minimized. In another approach, molecular fragment libraries are searched to 
find the fragments with certain level of activities against selected multiple 
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targets, and the identified fragments are further optimized into more potent 
bigger-sized multi-target active agents96. Optimizing fragments with weak 
multiple activities into potent multi-target drug-like agents can be more easily 
achieved for targets sharing a conserved binding site97. As binding sites 
become more dissimilar, it is increasingly difficult to improve and adequately 
balance the high binding affinities needed to achieve acceptable in-vivo 
efficacy and safety. One way to reduce this difficulty is to explore synergistic 
targets, such that multi-target agents with modest activity at one or more of the 
relevant targets may still produce similar or better in-vivo effects compared 
with higher-affinity target-selective compounds98. 
 
Moreover, multi-target QSAR models for identification of multi-target 
agents99 and active agents against multiple bacterial100, fungal101,102 and 
viral100 species have been developed by incorporating  multi-target or species 
variations of binding-site features into the multi-target dependent molecular 
descriptors or species-dependent molecular descriptors, and stochastic Markov 
drug-binding process models. These multi-target QSAR models achieve high 
retrieval rates of 72%~85% and moderately low false-hit rates of 15%~28%. 
Development of multi-target QSAR models may be limited by the inadequate 
number of drug data for some of the targets or species. Moreover, the 
molecular size of the testing drugs needs to be in a certain range for accurate 
computation of multi-target dependent or species-dependent molecular 
descriptors, which in some cases may also affect one’s capability for 




Multi-target based in-silico methods have been increasingly explored and have 
shown promising potential as virtual screening tools for identifying selective 
multi-target agents. The capability of these methods may be further enhanced 
by incorporating knowledge of newly discovered selective multi-target agents 
from the current and future drug discovery efforts85,86, and by the 
improvement of virtual screening methods103-109.  
1.5 Objectives and outline of this work 
Overall, there are four major objectives for this work.  
1. To construct high performance virtual screening tools for searching 
potential inhibitors or antagonists through screening large chemical 
libraries.  
2. To evaluate the robustness of our virtual screening tools. In this work, 
sparsely distributed active compounds are used to achieve this objective.  
3. To search potential c-Src and VEGFR-2 selective kinase inhibitors 
applying the developed virtual screening tools. 
4. To build combinatorial support vector machines (C-SVMs) models 
applying the developed virtual screening tools to search dual inhibitors of 
kinase pairs. 
 
In summary, this work is aimed at the development, evaluation and application 
of high performance virtual screening tools. More specifically, the study seeks 
to search potential single kinase inhibitors (c-Src and VEGFR-2) and multi-
target kinase inhibitors through screening large compound libraries. The 
present study may shed some light on the capability of machine learning based 
virtual screening methods in searching potential active agents from large 
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compound libraries at low false-hit rates, which could help in the lead 
discovery and optimization. 
 
The complete outline of this thesis is as follows: In Chapter 1, an introduction 
to virtual screening in drug discovery is described. Machine learning method 
is compared with other virtual screening method according to the literature 
review. In addition, the importance of potential kinase inhibitors discovery and 
in silico approaches of multi-target kinase discovery are presented.  
 
In Chapter 2, methods used in this work are described. In particular, the 
dataset quality analysis, the molecular descriptors, various statistical learning 
methods used in this work, and the model evaluation methods are presented in 
more detail. 
 
Chapter 3 is devoted to the development of high performance virtual screening 
tools. In particular, putative negative dataset is involved in training dataset to 
build SVM model to improve the performance of virtual screening. The 
performance of this virtual screening platform is evaluated using four datasets: 
HIV-1 protease inhibitors, DHFR inhibitors, Dopamine antagonists and CNS 
active agents. The results of screening 2.98M PubChem database using this 
platform show that the hit-rates are comparable and the enrichment factors are 
substantially better than the best results of other virtual screening (VS) tools. 
 
Chapter 4 is devoted to the evaluation of the virtual screening tools developed 
in Chapter 3 by using sparsely distributed active compounds. SVM models are 
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trained by regularly sparse datasets of 100 actives and very sparse datasets of 
40 datasets from six MDDR biological target classes. These models’ 
performance of virtual screening PubChem and MDDR database show that the 
platform developed in Chapter 3 has substantial capability in identifying novel 
active compounds from sparse active datasets at low false-hit rates. 
 
In Chapter 5, virtual screening models of kinase c-Src and VEGFR-2 
inhibitors are built using the method discussed in Chapter 3 to screen large 
compound libraries. Independent dataset and MDDR screening results show 
that rational c-Src and VEGFR-2 hits are given by our virtual screening tools. 
 
In Chapter 6, combinatorial support vector machines (C-SVMs) models were 
provided as virtual screening tools for searching dual-inhibitors of 11 
combinations of 9 anticancer kinase targets (EGFR, VEGFR, PDGFR, Src, 
FGFR, Lck, CDK1, CDK2, GSK3). In particular, C-SVMs method was 
compared to other VS methods DOCK Blaster, kNN and PNN against the 
same sets of kinase inhibitors and 1.02M Zinc clean-leads dataset. 
 
Finally, in the last chapter, Chapter 7, major findings and contributions of 
current work for the development and application of high performance virtual 
screening tools were discussed. Limitations and suggestions for future studies 




Chapter 2 Methods 
Machine learning based virtual screening for drug leads discovery will 
normally consist of three main components: (1) pharmaceutical agent datasets 
and chemical compound libraries (section 2.1), (2) physicochemical and 
structural descriptions of the compounds in the dataset (section 2.2 ) and (3) a 
statistical learning technique used to correlate the first two components 
(section 2.3). In this chapter, these three components are described and all the 
methods used in this work for developing virtual screening model are featured. 
Methods that are used for checking the validity and usefulness of virtual 
screening models are also described (section 2.4). 
2.1 Datasets  
2.1.1 Data source  
Data accessibility is critical for the success of a drug discovery and 
development. Huge amounts of small molecules and their related information 
have been accumulated in scientific literatures and databases. Some important 
small molecule databases are given in Table 2-1.  
 
In this work, datasets are mainly collected from the journals (Bioorganic & 
Medicinal Chemistry Letters, Bioorganic & Medicinal Chemistry, European 
Journal of Medicinal Chemistry, European Journal of Organic Chemistry and 
Journal of Medicinal Chemistry,etc)  and databases (BindingDB110, MDDR, 
PubChem and ZINC111, etc).   
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PubChem  http://nihroadmap.nih.gov 
ZINC  http://zinc.docking.org/  
ChEMBL http://www.ebi.ac.uk/chembl/  
DrugBank  http://www.drugbank.ca/  
eMolecules  http://www.emolecules.com/  
WOMBAT http://www.sunsetmolecular.com 
 
2.1.2 Data quality analysis  
The development of reliable pharmacological properties classification models 
depends on the availability of high quality pharmacological property 
descriptor data with low experimental errors112. Ideally, these pharmacological 
properties descriptors should be measured by a single protocol so that different 
compounds can be reliably compared with each other. However, some 
pharmacological properties descriptors have been measured only for a limited 
number of compounds and these data are rarely determined by the same 
protocol. Thus data selection has been primarily based on comparison of data 
of compounds commonly studied by different protocols, and incorporation of 
additional experimental information. For this work, several methods are 
adopted to ensure that inter-laboratory variations in experimental protocols do 
not significantly affect the quality of the training sets. The sources for the 
Chapter 2 Methods 
  33 
pharmacological property descriptor data for each compound were 
investigated to ensure that there were no wide variations in experimental 
protocols from those of the majority of the compounds in the training set. 
Compounds that were investigated in more than one source are used to 
estimate the quality of each source. It is assumed that the most common range 
of the pharmacological properties descriptor data for the compounds 
investigated in more than one source was used to select compounds for the 
different classes113.  
 
2.1.3 Determination of structural diversity 
Structural diversity of a collection of compounds can be evaluated by using 
the Diversity Index (DI), which is the average value of the similarity between 
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where ),( jisim  is a measure of similarity between compounds i  and j , D is 
the dataset and |D| is set cardinality (number of elements of the set). The 
dataset is more diverse when DI approaches 0. Tanimoto coeeficient115 were 
used to compute ),( jisim  in this study, 
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2.2 Molecular descriptors  
2.2.1 Types of molecular descriptors  
Molecular descriptors have been extensively used in deriving structure-activity 
relationships116,117, quantitative structure activity relationships118,119, and 
machine learning prediction models for pharmaceutical agents120-123. A 
descriptor is “the final result of a logical and mathematical procedure which 
transforms chemical information encoded within a symbolic representation of 
a compound into a useful number or the result of some standardized 
experiment”. A number of programs e.g. DRAGON124, Molconn-Z125, 
MODEL126, Chemistry Development Kit (CDK)127,128, JOELib129 and Xue 
descriptor set130, are available to calculate chemical descriptors. These 
methods can be used for deriving >3,000 molecular descriptors including 
constitutional descriptors, topological descriptors, RDF descriptors131, 
molecular walk counts132, 3D-MoRSE descriptors133, BCUT descriptors134, 
WHIM descriptors135, Galvez topological charge indices and charge 
descriptors136, GETAWAY descriptors137, 2D autocorrelations, functional 
groups, atom-centred descriptors, aromaticity indices138, Randic molecular 
profiles139, electrotopological state descriptors140, linear solvation energy 
relationship descriptors141, and other empirical and molecular properties. Not 
all of the available descriptors are needed for representing features of a 
particular class of compounds. Moreover, without properly selecting the 
appropriate set of descriptors, the performance of a developed ML VS tool 
may be affected to some degrees because of the noise arising from the high 
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redundancy and overlapping of the available descriptors. In this work, the Xue 
descriptor set and 98 1D and 2D descriptors were used. These 98 descriptors 
were selected from the descriptors derived from MODEL program by 
discarding those that were redundant and unrelated to the problem studied 
here. The Xue descriptor set and these 98 descriptors are listed in Table 2-2 
and Table 2-3. 
Table 2-2 Xue descriptor set used in this work. 
 






18  Molecular weight, Number of rings, rotatable bonds, H-
bond donors, and H-bond acceptors, Element counts 
Molecular connectivity 
and shape  
28  Molecular connectivity indices, Valence molecular 
connectivity indices, Molecular shape Kappa indices, 
Kappa alpha indices, flexibility index 
Electro-topological 
state  
97  Electrotopological state indices, and Atom type 
electrotopological state indices, Weiner Index, Centric 
Index, Altenburg Index, Balaban Index, Harary Number, 
Schultz Index, PetitJohn R2 Index, PetitJohn D2 Index, 
Mean Distance Index, PetitJohn I2 Index, Information 
Weiner, Balaban RMSD Index, Graph Distance Index  
Quantum chemical 
properties  
31  Polarizability index, Hydrogen bond acceptor basicity 
(covalent HBAB), Hydrogen bond donor acidity (covalent 
HBDA), Molecular dipole moment, Absolute hardness, 
Softness, Ionization potential, Electron affinity, Chemical 
potential, Electronegativity index, Electrophilicity index, 
Most positive charge on H, C, N, O atoms, Most negative 
charge on H, C, N, O atoms, Most positive and negative 
charge in a molecule, Sum of squares of charges on 
H,C,N,O and all atoms, Mean of positive charges, Mean of 
negative charges, Mean absolute charge, Relative positive 
charge, Relative negative charge  
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Geometrical properties 25 Length vectors (longest distance, longest third atom, 4th 
atom), Molecular van der Waals volume, Solvent 
accessible surface area, Molecular surface area, van der 
Waals surface area, Polar molecular surface area, Sum of 
solvent accessible surface areas of positively charged 
atoms, Sum of solvent accessible surface areas of 
negatively charged atoms, Sum of charge weighted solvent 
accessible surface areas of positively charged atoms, Sum 
of charge weighted solvent accessible surface areas of 
negatively charged atoms, Sum of van der Waals surface 
areas of positively charged atoms, Sum of van der Waals 
surface areas of negatively charged atoms, Sum of charge 
weighted van der Waals surface areas of positively 
charged atoms, Sum of charge weighted van der Waals 
surface areas of negatively charged atoms, Molecular 
rugosity, Molecular globularity, Hydrophilic region, 
Hydrophobic region, Capacity factor, Hydrophilic-
Hydrophobic balance, Hydrophilic Intery Moment, 
Hydrophobic Intery Moment, Amphiphilic Moment 
 











18 Number of C,N,O,P,S, Number of total atoms, Number of  rings, 
Number of bonds, Number of non-H bonds, Molecular weight,, 
Number of rotatable bonds, number of H-bond donors, number of H-
bond acceptors, Number of 5-member aromatic rings, Number of 6-
member aromatic rings, Number of N heterocyclic rings, Number of O 
heterocyclic rings, Number of S heterocyclic rings. 
Chemical 
properties 




35 Schultz molecular topological index, Gutman molecular topological 
index, Wiener index, Harary index, Gravitational topological index, 
Molecular path count of length 1-6, Total path count, Balaban Index J, 
0-2th valence connectivity index, 0-2th order delta chi index, Pogliani 
index, 0-2th Solvation connectivity index, 1-3th order Kier shape 
index, 1-3th order Kappa alpha shape index, Kier Molecular Flexibility 
Index, Topological radius, Graph-theoretical shape coefficient, 
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42 Sum of Estate of atom type sCH3, dCH2, ssCH2, dsCH, aaCH, sssCH, 
dssC, aasC, aaaC, sssC, sNH3, sNH2, ssNH2, dNH, ssNH, aaNH, dsN, 
aaN, sssN, ddsN, aOH, sOH, ssO, sSH; Sum of Estate of all heavy 
atoms, all C atoms, all hetero atoms, Sum of Estate of H-bond 
acceptors, Sum of H Estate of atom type HsOH, HdNH, HsSH, 
HsNH2, HssNH, HaaNH, HtCH, HdCH2, HdsCH, HaaCH, HCsats, 
HCsatu, Havin, Sum of H Estate of H-bond donors 
 
In our work, descriptors were computed from the 3D structure of the 
compounds. The 2D structure of each of the compounds was generated by 
using ChemDraw or downloaded from other database like PubChem, 
BindingDB110 database and was subsequently converted into 3D structure by 
using CORINA142. All the generated geometries had been fully optimized 
without symmetry restrictions. The 3D structure of each compound was 
manually inspected to ensure that the chirality of each chiral agent was 
properly generated. All salts and elements, such as sodium or calcium, were 
removed prior to descriptor calculation. 
 
2.2.2 Scaling of molecular descriptors 
Chemical descriptors are normally scaled before they can be employed for 
machine learning. Scaling of chemical descriptors ensures that each descriptor 
has an unbiased contribution in creating the prediction models143. Scaling can 
be done by number of ways e.g. auto-scaling, range scaling, Pareto scaling144, 
and feature weighting143. In this work, range scaling is used to scale the 
chemical descriptor data. Range scaling is done by dividing the difference 
between the descriptor value and the minimum value of that descriptor with 
the in range of that descriptor:  
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                                 (3) 
Where , ij , dj,max and dj,min are the scale descriptor value of 
compound i, absolute descriptor value of compound i , maximum and 
minimum  values of descriptor j respectively. The scaled descriptor value falls 
in the range of 0 and 1.  
2.3 Machine learning classification methods  
Machine learning classification methods employ computational and statistical 
methods to construct mathematical models from training samples which is 
used to classify independent test sample. The training samples are represented 
by vectors which can binary, categorical or continuous.  Machine learning can 
be divided into two types: Supervised and Unsupervised. Supervised machine 
learning, as the name indicates, generally needs feeding which generally 
involves already labeled or classified training data. Example of supervised 
machine learning includes Support Vector Machine, Artificial Neural 
Network, Decision tree learning, Inductive logic programming, Boosting, 
Gaussian process regression etc. Unsupervised machine learning, as the name 
indicates, gets unlabeled training data and the learning task involves finding 
the organization of data. Examples of unsupervised machine learning include 
Clustering, Adaptive Resonance Theory, and Self Organized Map (SOM). 
Some of machine learning methods employed in this work are SVM, 
Probabilistic Neural Network (PNN), k nearest neighbor (KNN). They are 
explained below in subsequent sub sections. For a comparative study, 




2.3.1 Support vector machines method 
The process of training and using a SVM VS model for screening compounds 
based on their molecular descriptors is schematically illustrated in Figure 2-1. 
SVM is based on the structural risk minimization principle of statistical 
learning theory145,146, which consistently shows outstanding classification 
performance, is less penalized by sample redundancy, and has lower risk for 
over-fitting147,148. In linearly separable cases, SVM constructs a hyper-plane to 
separate active and inactive classes of compounds with a maximum margin. A 
compound is represented by a vector xi composed of its molecular descriptors. 
The hyper-plane is constructed by finding another vector w and a parameter b 
that minimizes 2w  and satisfies the following conditions: 
 1,  for 1i ib y     w x  Class 1 (active)   (4) 
 1,  for 1i ib y     w x  Class 2 (inactive)   (5) 
where yi is the class index, w is a vector normal to the hyperplane, /b w  is 
the perpendicular distance from the hyperplane to the origin and 2w  is the 
Euclidean norm of w. Base on w and b, a given vector x can be classified by 
f(x) = [( ) ]sign b w x .  A positive or negative f(x) value indicates that the 
vector x belongs to the active or inactive class respectively.  
 
In nonlinearly separable cases, which frequently occur in classifying 
compounds of diverse structures46-48,63,149-151, SVM maps the input vectors into 
a higher dimensional feature space by using a kernel function K(xi, xj). We 
used RBF kernel  
2 2/ 2( , ) j ii jK e
  x xx x which has been extensively used and 
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consistently shown better performance than other kernel functions24,152,153. 
Linear SVM can then applied to this feature space based on the following 
decision function: 0
1




f sign y K b

 x x x , where the coefficients i0 
and b are determined by maximizing the following Langrangian expression: 
1 1 1
1 ( , )
2
l l l
i i j i j i j
i i j
y y K  
  








0 . A positive or negative f(x) value indicates that the vector x is an 




Figure 2-1 Schematic diagram illustrating the process of the training a 
prediction model and using it for predicting active compounds of a compound 
class from their structurally-derived properties (molecular descriptors) by 
using support vector machines. A, B, E, F and (hj, pj, vj,…) represents such 




2.3.2 K-nearest neighbor method 
k-NN is illustrated in Figure 2-2. k-NN measures the Euclidean distance 
2
iD  x x  between a compound x and each individual inhibitor or non-
inhibitor xi in the training set154,155. A total of k number of vectors nearest to 
the vector x are used to determine the decision function f(x): 
1






 x x                                                        (6) 
where ( , ) 1 if  and ( , ) 0 if a b a b a b a b      , argmax is the maximum 
of the function, V is a finite set of vectors {v1,...,vs}  and ˆ ( )f x  is an estimate 
of f(x). Here estimate refers to the class of the majority compound group (i.e. 
inhibitors or non-inhibitors) of the k nearest neighbours.  
 
2.3.3 Probabilistic neural network method 
As illustrated in Figure 2-3, PNN is a form of neural network designed for 
classification through the use of Bayes’ optimal decision rule113 
 ( ) ( )i i i j j jh c f h c fx x                    
where hi and hj are the prior probabilities, ci and cj are the costs of 
misclassification and fi(x) and fj(x) are the probability density function for 
class i and j respectively. An unknown vector x is classified into population i 
if the product of all the three terms is greater for class i than for any other class 
j (not equal to i). In most applications, the prior probabilities and costs of 
misclassifications are treated as being equal. The probability density function 




           
1






  x xx                  (7)
  
where n is the sample size,  is a scaling parameter which defines the width of 
the bell curve that surrounds each sample point, W(d) is a weight function 
which has its largest value at d = 0 and (x – xi) is the distance between the 
unknown vector and a vector in the training set. The Parzen’s nonparametric 
estimator was later expanded by Cacoullos for the multivariate case. 
          ,1 1,1
11 1






g x x W
n   
                 (8) 
The Gaussian function is frequently used as the weight function 
because it is well behaved, easily calculated and satisfies the conditions 
required by Parzen’s estimator. Thus the probability density function for the 
multivariate case becomes 
           
2
1 1







       x                (9)
  
The network architectures of PNN are determined by the number of 
compounds and descriptors in the training set. There are 4 layers in a PNN. 
The input layer provides input values to all neurons in the pattern layer and 
has as many neurons as the number of descriptors in the training set. The 
number of pattern neurons is determined by the total number of compounds in 
the training set. Each pattern neuron computes a distance measure between the 
input and the training case represented by that neuron and then subjects the 
distance measure to the Parzen’s nonparametric estimator. The summation 
layer has a neuron for each class and the neurons sum all the pattern neurons’ 
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output corresponding to members of that summation neuron’s class to obtain 
the estimated probability density function for that class. The single neuron in 
the output layer then estimates the class of the unknown vector x by 
comparing all the probability density function from the summation neurons 






Figure 2-2 Schematic diagram illustrating the process of the prediction of 
compounds of a particular property from their structure by using a machine 
learning method – k-nearest neighbors (k-NN). A, B: feature vectors of agents 
with the property; E, F: feature vectors of agents without the property; feature 
vector (hj, pj, vj,…) represents such structural and physicochemical properties 





Figure 2-3 Schematic diagram illustrating the process of the prediction of the 
prediction of compounds of a particular property from their structure by using 
a machine learning method –probabilistic neural networks (PNN). A, B: 
feature vectors of agents with the property; E, F: feature vectors of agents 
without the property; feature vector (hj, pj, vj,…) represents such structural and 





2.3.4 Tanimoto similarity searching method  
Compounds similar to at least one compound in a training dataset can be 





















                           
 (10)
 
where l is the number of molecular descriptors. A compound i is 
considered to be similar to a known active j in the active dataset if the 
corresponding sim(i,j) value is greater than a cut-off value. In this work, the 
similarity search was conducted for MDDR compounds. Therefore, in 
computing sim(i,j), the molecular descriptor vectors xis were scaled with 
respect to all of the MDDR compounds. The cut-off values for similarity 
compounds are typically in the range of 0.8 to 0.9157,158. A stricter cut-off 
value of 0.9 was used in this work 
2.4 Virtual screening model validation and performance 
evaluation 
2.4.1 Model validation 
One of the objectives of modeling is to allow prediction of the 
pharmacological properties of compounds which have not been clinically and 
biologically tested. Thus it is important to determine the ability of the derived 
pharmacological property prediction models to predict the properties of 
compounds that are not present in the training set. The validation methods 
used in this work are 5-fold cross validation and independent validation 
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dataset. In 5-fold cross validation, compounds are randomly divided into five 
subsets of approximately equal size. Four subsets are used as a training set for 
developing a model; the remaining one is used as a test set for evaluating the 
prediction performance of that model. This process is repeated five times such 
that every subset is used as a testing set once. The average accuracy of the five 
time models is used for measuring the generalization capability of that method. 
However, cross validation methods have a tendency of underestimating the 
prediction capability of a classification model, especially if important 
molecular features are present in only a minority of the compounds in the 
training set159,160. Thus a model having low cross-validation accurary can still 
be predictive159. This lead to some studies which suggest that an independent 
validation dateset may provide a more reliable estimation of the prediction 
capability of a pharmacological property model161,162. An independent 
validation dataset should ideally be obtained independently from the training 
set and should be representative of the training set so that it can properly 
assess the prediction capabilities of the pharmacological property model. It is 
even better if the validation dataset is composed of newly published 
experimentally validated chemical compounds with a particular 
pharmacological property.  
 
2.4.2 Performance evaluation methods  
The performance of virtual screening model can be evaluated by the quantity 
of true positives TP (pharmaceutical agents possessing a specific 
pharmacological property), true negatives TN (pharmaceutical agents not 
possessing a specific pharmacological property), false positives FP 
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(pharmaceutical agents not possessing a specific pharmacological property but 
predicted as agents possessing the specific pharmacological property), false 
negatives FN (pharmaceutical agents possessing a specific pharmacological 
property but predicted as agents not possessing the specific pharmacological 
property). Sensitivity and specificity are the prediction accuracy for 
pharmaceutical agents possessing a specific pharmacological property and 
agents not possessing that pharmacological property respectively. The overall 
prediction accuracy (Q) and Matthews correlation coefficient (MCC)163 are 
used to measure the overall prediction performance: 
SE FNTP
TP
                                                                                   (11) 
SP FPTN
TN




                                                                    (13) 
    FPTNFNTNFPTPFNTP
FPFNTNTPMCC 

                            (14) 
The model performance in screening large libraries can be typically 
measured33 by yield (percentage of known positives predicted as virtual hits), 
hit-rate (percentage of virtual hits that are known positives), false hit-rate 
(percentage of virtual hits that are known negatives) and enrichment factor EF 
(magnitude of hit-rate improvement over random selection):  
Yield = SE                                     
(15) 
Hit-rate = TP/(TP+FP)                                   
(16) 




Enrichment factor EF = hit-rate / (TP+FN)/(TP+FN+TN+FP)               
(18) 
 
2.4.3 Overfitting problem and its prevention 
Overfitting is the phenomenon of building a model that agrees well with the 
observed data but has no predictive ability (it does not agree with unseen or 
future data). It is a major concern in machine learning classification methods. 
There are two main types of overfitting: (1) using a model that is more flexible 
than it needs to be and (2) using a model that includes irrelevant descriptors160. 
A frequently used method for checking whether a prediction system is 
overfitted is to compare the prediction accuracies determined by using cross 
validation methods with those determined by using independent validation 
sets160. An over-fitted classification system is expected to have much higher 
prediction accuracy for the cross validation sets than that for the independent 
validation sets.  
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Chapter 3 Development and Evaluation of High 
Performance Virtual Screening Tools 
Support vector machines (SVM) and other machine-learning (ML) methods 
have been explored as ligand-based virtual screening (VS) tools for 
facilitating lead discovery. While exhibiting good hit selection performance, in 
screening large compound libraries, these methods tend to produce lower hit-
rate than those of the best performing VS tools, partly because their training-
sets contain a limited spectrum of inactive compounds. In this chapter, we 
tested whether the performance of SVM can be improved by using training-
sets of diverse inactive compounds. 
3.1 Introduction 
Virtual screening (VS) has been extensively explored for facilitating lead 
discovery 27,37,164,165 and for identifying agents of desirable pharmacokinetic 
and toxicological properties26,166. Machine learning (ML) methods have 
recently been used for developing ligand-based VS (LBVS) tools36,46-49,61,62,167 
to complement or to be combined with structure-based VS (SBVS) 37,52-55,59,65-
67,69,168-170 and other LBVS27-31 tools aimed at improving the coverage, 
performance and speed of VS tools. 
 
ML methods have been used as part of the efforts to overcome several 
problems that have impeded progress in more extensive applications of SBVS 
and LBVS tools33,37. These problems include the vastness and sparse nature of 
chemical space that needs to be searched, limited availability of target 
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structures (only 15% of known proteins have known 3D structures), 
complexity and flexibility of target structures, and difficulties in computing 
binding affinity and solvation effects. LBVS may in some cases limit the 
diversity of hits due to the bias of training molecules168. Therefore, alternative 
approaches that enhance screening speed and compound diversity without 
relying on target structural information are highly desired. ML methods have 
been  explored for developing such alternative VS tools46,47,61 because of their 
high-CPU speed (100K data points per hour on 3GHz PC)62 and capability for 
covering highly diverse spectrum of compounds171. 
 
The reported performance of various LBVS and SBVS tools in screening 
compound libraries of >90,000 compounds is summarized in Table 3-1. 
Caution needs to be raised about straightforward comparison of these reported 
results, which might be misleading because the outcome of VS strongly 
depends on the datasets used. The dataset-dependence of VS performance can 
be illustrated by a test shown in a subsequent section 3.4 of this chapter. 
Therefore, the listed results should be viewed as providing very crude pictures 
about the reported VS performances. While exhibiting equally good hit 
selection performance, in screening extremely-large (≥1 million) and large 
(100,000~900,000) libraries, the currently developed ML tools tend to show 
lower hit-rate (ratio of known hits and the predicted hits) and, in some cases, 
lower enrichment factor (magnitude of hit-rate improvement over random 
selection) than the best performing SBVS tools. For instance, in screening 
extremely-large libraries, the reported yield (percentage of known hits 
predicted), hit-rate and enrichment factor of ML tools are in the range of 
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55%~81%, 0.2%~0.7% and 110~795 respectively 172, compared to those of 
62%~95%, 0.65%~35% and 20~1,200 by SBVS tools 46-51. While in screening 
libraries of ~98,000 compounds the reported hit-rates of some ML tools are 
comparable to those of SBVS tools, their enrichment factors are substantially 
smaller. A lower hit-rate gives rise to a higher number of false-hits and a 
lower enrichment factor suggests that there might be bigger room for further 
optimizing a VS tool. Hence, there is a need for further improving the hit-rate 
and enrichment factor of ML tools. It is not uncommon for the pharmaceutical 
industry to screen >1 million compounds per high-throughput screening 
campaign172. The goal of virtual screening is the drastic reduction of 
compound libraries to a manageable size for synthesis and biological testing. 
Therefore, improvement of hit-rate and enrichment factor is highly desirable 
for developing practically useful ML tools for LBVS. 
 
Two approaches have been explored for minimizing false hits. One is the 
selection of top-ranked hits, which has been extensively used in LBVS46-51 and 
SBVS52-57. The other is the elimination of potentially unpromising hits in pre-
screening stage by using such filters as Lipinski’s rule of five58 65, and 
recognition of  pharmacophore 54 and specific chemical groups or interaction 
patterns52,53,59,60. In addition to the application of these approaches, the 
performance of ML tools in screening large libraries may be further improved 
by using training sets of more diverse spectrum of compounds to develop 
more optimally performing ML models.  These models have been generated 
by using two-tier supervised classification ML methods36,46-49,61-63, which 
require training sets of diverse spectrum of active and inactive compounds. 
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The training inactive compounds in these models have been collected from up 
to a few hundred known inactive compounds or/and putative inactive 
compounds from up to a few dozen biological target classes in MDDR 
database36,46-49,61-63, which may not always be sufficient to fully represent 
inactive compounds in the vast chemical space, thereby making it difficult to 
optimally minimize false hit prediction rate of ML models. 
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Table 3-1 Comparison of the reported performance of different virtual screening (VS) methods in screening large libraries of 
compounds. 
 
Type of VS method 







Compounds screened Virtual hits selected by 
VS method 














































375~4.5K 0.28%~3% 5~231 2%~ 30% 
 




libraries ( ≥1M) 
Machine learning 
- SVM (2)46,48,62  
2.5M 22~46 0.0009%~ 
0.0018% 
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SVM 2.986M 2351 0.076% 8157 0.27% 1833 78.0% 22.5% 296 
SVM 2.986M 225 0.007% 160 0.0054% 118 52.4% 73.8% 10543 
SVM 2.986M 37 0.0012% 299 0.01% 23 62.2% 7.7% 6417 




In this work, we examined to what extent hit rate and enrichment factor of ML 
tools can be improved by using training-sets of more diverse spectrum of 
inactive compounds. A widely used and better performing ML method, 
support vector machines (SVM) 36,46,47,49,62,167, was used to develop SVM 
models for identifying active compounds of single mechanism (HIV-1 
protease inhibitors, dihydrofolate reductase (DHFR) inhibitors, dopamine 
receptor antagonists) and multiple mechanisms (central nervous system (CNS) 
active agents). HIV-1 protease inhibitors form an important class of anti-HIV 
agents some of which have been successfully used clinically41. DHFR 
inhibitors are useful for the treatment of microbial infections173, cancer174, and 
parasitic diseases175. Dopamine antagonists have been used as antipsychotic 
agents176 and for the treatment of cervical dystonia177, vertigo178, and 
gastrointestinal motility disorders179. CNS active agents are composed of a 
diverse spectrum of CNS acting compounds that produce anxiolytic, 
antipsychotic, antidepressant, analgesic, anticonvulsant, antimigraine, 
antiischemic, antiparkinsonian, nootropic, neurologic, epileptic, neuroleptic, 
neurotropic, neuronal injury inhibiting,  narcotics antagonizing, and CNS 
stimuating effects180. Because of their diverse therapeutic applications and 
structural frameworks, these compounds are highly useful for testing the 
performance of SVM and other ML tools in LBVS of large compound 
libraries. 
 
Our SVM models were trained by using known active compounds and 
putative inactive compounds extracted from compound families that contain 
no known active compound. Compound families can be generated by 
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clustering distinct compounds of chemical databases into groups of similar 
structural and physicochemical properties29. The developed SVM models were 
tested in screening libraries of 2.986 million compounds from the PubChem 
database that are not in the training sets of these SVM models. The yields, hit-
rates and enrichment factors derived from these tests were compared with 
those of SBVS and other LBVS tools applied in the screening of extremely-
large libraries to determine to which extent the overall performance of SVM 
models can be enhanced and whether it is comparable to that of the best 
performing VS tools reported in the literature. To further evaluate whether our 
SVM models predict active and inactive compounds rather than membership 
of certain compound families, distribution of the predicted active and inactive 
compounds in the compound families were analyzed. 
3.2 Methods 
3.2.1 Collection of active compounds 
Table 3-2 gives the statistics of collected active compounds for the four active 
compound classes and their structural diversity index (DI) (defined in 
Methods Chapter section 2.1.3). The structures of a few selected compounds 
for each class are shown in Figure 3-1. For comparison of structural diversity 
of the compounds in these and those of the other structurally diverse classes, 
the statistics and DI values of several such classes are also listed in Table 3-2. 
A total of 5,161 HIV-1 protease inhibitors, with log (IC50) values in the range 
of -7.85 to -3.30, were selected from the HIV/OI Enzyme Inhibition Database 
of the National Institute of Allergy and Infectious Diseases of NIH. 76.6% of 
which are peptide-based inhibitors (66% and 5% are peptidomimetics and 
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symmetry-based inhibitors respectively) and 23.4% are non-peptide-based 
inhibitors. The quality of these inhibitors were further validated against 
literature reports we found from the literature database PUBMED to ensure 
that they have been described as HIV-1 protease inhibitors with IC50 values in 
the range of binding potencies considered to be important in various cases. 
Table 3-2 Diversity index (DI) and number of HIV protease inhibitors, DHFR 
inhibitors, dopamine antagonists, and CNS active agents used for developing 
support vector machines ligand-based virtual screening tools. For comparison, 
relevant data of several other compound classes of highly diverse structures 
are also included. These compound classes are arranged in descending order of 
structural diversity. 
 
Chemical Class No. of Active Compounds DI Value 
Blood-brain barrier penetrating agents 181  276 0.430 
FDA approved drugs 1,121 0.495 
NCI diversity set 1,804 0.544 
P-glycoprotein substrates 130 116 0.555 
CYP 2D6 inhibitors 180 0.575 
CNS active agents (this work) 16,182 0.578 
CYP 2D6 substrates 198 0.588 
Human intestine absorbing agents 182 131 0.596 
Estrogen receptor agonists 167 243 0.618 
HIV protease inhibitors (this work) 5,161 0.626 
DHFR inhibitors (this work) 755 0.719 
Dopamine antagonists (this work) 1,184 0.741 
 
DHFR inhibitors were collected from a publication183. We were able to use 
our software182 to generate molecular descriptors of 755 of the 756 collected 
inhibitors. We collected 1,184 distinct dopamine antagonists from three 
separate sources, which include 1,163 from MDDR database, 126 from 
PubChem database, and 41 from a publication184. CNS active agents were 
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retrieved from those compounds in MDDR database annotated as anxiolytic, 
antipsychotic, antidepressant, analgesic (non-opioid and opioid), 
anticonvulsant, antimigraine, antiischemic (cerebral), antiparkinsonian, 
stimulant in central, antagonist to narcotics, centrally acting agent, nootropic 
agent, neurologic agent, epileptic, and neuronal injury 
inhibitor/neuroleptic/neurotropic. We were able to use our software182 to 
derive molecular descriptors for 16,182 of the collected 16,390 non-redundant 
CNS active compounds. Molecular descriptorsof part of active compounds 
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Figure 3-1 Structures of the selected HIV protease inhibitors, DHFR 
inhibitors, dopamine antagonists, and CNS active agents. The PubChem 





3.2.2 Generation of putative inactive compounds 
Apart from the use of known inactive compounds and active compounds of 
other biological target classes as putative inactive compounds36,46-49,61-63, a 
new approach extensively used for generating inactive proteins in ML 
classification of various classes of proteins185-187 may be applied for generating 
putative inactive compounds. An advantage of this approach is its 
independence on the knowledge of known inactive compounds and active 
compounds of other biological target classes, which enables more expanded 
coverage of the “inactive” chemical space in cases of limited knowledge of 
inactive compounds and compounds of other biological classes. A drawback 
of this approach is the possible inclusion of some undiscovered active 
compounds in the “inactive” class, which may affect the capability of ML 
methods for identifying novel active compounds. As will be demonstrated, 
such an adverse effect is expected to be relatively small for many biological 
target classes. 
 
In applying this approach to proteins, all known proteins are clustered into 
~8,900 protein families based on the clustering of their amino acid 
sequences129, and a set of putative inactive proteins can be tentatively 
extracted from a few representative proteins in those families without a single 
known active protein. Undiscovered active proteins of a specific functional 
class typically cover no more than a few hundred families, which gives a 
maximum possible “wrong” family representation rate of <10% even when all 
of the undiscovered active proteins are misplaced into the inactive class188. 
Importantly, inclusion of the representative of a “wrong” family into the 
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inactive class does not preclude other active family members from being 
classified as active. Statistically, a substantial percentage of active members 
can be classified by ML methods as active even if its family representative is 
in the inactive class188. Therefore, in principle, a reasonably good ML model 
can be derived from these putative inactive samples, which has been 
confirmed by a number of studies185-188. 
 
In a similar manner, known compounds can be grouped into compound 
families by clustering them in the chemical space defined by their molecular 
descriptors29,189. As ML methods predict compound activities based on their 
molecular descriptors, in developing ML tools, it makes sense to cluster as 
well as to represent compounds in terms of molecular descriptors. By using a 
K-means method 29,189 and molecular descriptors computed from our own 
software182, we generated 7,990 cluster families from the available compounds 
in PubChem database, which is consistent with the 12,800 compound-
occupying neurons (regions of topologically close structures) for 26.4 million 
compounds of up to 11 atoms3, and the 2,851 clusters for 171,045 natural 
products190. Analogue groups such as steroids and catecholamines are 
distributed in a few families. Active compounds in extensively studied target 
classes such as those of HIV-1 protease inhibitors, DHFR inhibitors, and 
dopamine antagonists are distributed in 770, 135, and 799 families 
respectively.  Because of the extensive effort in searching the known 
compound libraries for identifying active compounds in these target classes, 
the number of undiscovered “active” families in PubChem database is 
expected to be relatively small, most likely no more than several hundred 
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families. The ratio of the undiscovered “active” families (hundreds on less) 
and the families that contain no known active compound (6,000~7,000 based 
on current version of PubChem) for these and possibly many other target 
classes is expected to be <15%. Therefore, putative inactive compounds can 
be generated by extracting a few representative compounds of those families 
that contain no known active compound, with a maximum possible “wrong” 
family representation rate of <15% even when all of the undiscovered active 
compounds are misplaced into the inactive class.  
 
CNS active agents are distributed in numerous biological target classes such as 
agonists, antagonists, regulators of G-protein coupled receptors and nuclear 
receptors, blockers and regulators of ion channels, substrates, inhibitors, 
activators, and regulators of transporters, and inhibitors and regulators of 
enzymes involved in the synthesis and metabolism of signalling molecules in 
the CNS system180. Therefore, agents in this multi-target class are expected to 
cover a significantly larger portion of the chemical space than those of a single 
target class, leading to a possibly higher “wrong” family representation rate 
because of the likelihood of higher number of undiscovered active families in 
the limited chemical space covered by the currently available compounds in 
existing databases. As a result, the quality of the putative non-CNS active 
compounds generated by the new approach may be affected to some extent. 
The new approach is expected to become more and more useful for multi-
target classes when the coverage of chemical space can be significantly 




There are 7,220, 7,855, 7,191, 3,440 families that contain no known HIV-1 
protease inhibitor, DHFR inhibitor, dopamine antagonist, and CNS active 
agent respectively. Thus datasets of 41,254 putative non- HIV-1 protease 
inhibitors, 44,856 putative non-DHFR inhibitors, 42,804 putative non-
dopamine antagonists, and 20,465 putative non-CAN active compounds were 
generated by random selection of 5~6 representative compounds from each of 
these families respectively.  
 
3.2.3 Molecular descriptors 
A total of 199 descriptors derived by using our software182 were used in this 
work. The details of the molecular descriptors are explained in Chapter 2 
Section 2.2. 
 
3.2.4 Development of support vector machines virtual 
screening tools 
SVM models for identifying HIV protease inhibitors, DHFR inhibitors, 
dopamine antagonists, and CNS active agents were developed by a procedure 
widely used for developing SVM protein classification models of optimal 
performance185-187. In the first step, active and inactive compounds were each 
divided into separate training, testing and independent evaluation sets. 
Specifically, active and inactive compounds were each clustered into groups 
based on their distance in the molecular descriptor space by using a 
hierarchical clustering method132 . An upper-limit of the largest separation of 
20 was used for each cluster. One representative compound was randomly 
selected from each group to form a training set that is sufficiently diverse and 
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broadly distributed in the descriptor space. One or up to 50% of the remaining 
compounds in each group were randomly selected to form the testing set. The 
selected compounds from each group were further checked to ensure that they 
are distinguished from those of other groups. The remaining compounds were 
used as the independent evaluation set, which are also of reasonable level of 
diversity. Moreover, an analysis of the compounds in each cluster shows that 
the majority of the compounds in a cluster are substantially different. Thus, the 
testing and independent evaluation sets are expected to have certain level of 
usefulness for performing their task of fine-tuning the parameter of a SVM 
model and for evaluating its prediction performance. In the second step, SVM 
models were trained by using the training set and their parameters were 
optimized by using the testing set. The SVM model with the best overall 
performance on both the testing and independent evaluation sets was selected 
as a VS tool. 
3.3 Assessment of virtual screening performance 
The developed SVM models for identifying HIV protease inhibitors, DHFR 
inhibitors, dopamine antagonists, and CNS active agents in screening 2.986 
million distinct compounds from the PubChem database that are not in the 
training sets of our developed SVM models. The performance of these SVM 
models is given in Table 3-3, which can be compared with the reported 
performance of other SBVS and LBVS tools listed in Table 3-1. There are 
2,351, 225, 37, and 664 known HIV protease inhibitors, DHFR inhibitors, 
dopamine antagonists, and CNS active agents in the PubChem database not in 
the training sets of our SVM models. Our SVM models were able to identify 
78.0%, 52.4%, 62.2%, and 66.6% of these known hits, which are comparable 
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to the range of 62%~95% by the SBVS tools52,65 and 55%~81% by other 
LBVS 46,48,62 tools in screening libraries of ≥1 million compounds, and they 
are also comparable to the percentages in screening libraries of 
98,400~344,500 compounds by other SBVS53-55,59,66,67,69,168-170 and LBVS 
tools29,31,36,47-49,62. These results suggest that our developed SVM models are 
equally effective in selecting potential hits in VS of large libraries. 
 
In addition to the exhibition of equally effective hit selection performance, our 
SVM models appear to show relatively lower “false” hit identification rate. 
Without the use of top-ranked cut-off or additional filter, our SVM models 
identified a total of 8,157, 160, 299, and 9,502 virtual hits for the four 
compound classes respectively, which are comparable to and in some cases 
smaller than those identified by SBVS52-55,59,65-67,69,168-170 and other 
LBVS29,36,46-48,62,150,151 tools even though a substantially larger number of 
compounds (2.983M vs. 98.4K~2.5M) were screened. As a result, smaller 
percentages of screened compounds were selected as virtual hits, which are in 
the range of 0.0054%~0.32% as compared to those of 0.08%~3% by SBVS 
tools52-55,59,65-67,69,168-170, 0.1%~5% by other reported ML models36,47-49,62, 
0.16%~82.% by clustering methods29 , and 1.15%~26% by pharmacophore 
models30,31,70,71. By using Lipinski’s rule of five58 as a filter, the numbers of 
identified virtual hits are further reduced to 333, 115, 209, and 8,035 for the 
four compound classes respectively, suggesting that introduction of such 
filters or combination with other VS methods may enable further reduction of 




The hit-rates of our SVM models are 22.5%, 73.8%, 7.7%, and 4.7% for the 
four classes of compounds respectively, which are comparable to those of 
0.65%~35% by SBVS tools and substantially improved against those of 
0.2%~0.7% by other reported SVM models in screening extremely large 
libraries. These hit-rates are also greater than the majority of the hit-rates in 
screening large libraries of 98,400~344,500 compounds by SBVS and other 
LBVS tools.  The enrichment factors of our SVM models are 296, 10,543, 
6,417, and 214 for the four classes of compounds respectively, which are 
substantially improved against those of 20~1,200 by SBVS tools and 110~795 
by other reported SVM models in screening extremely large libraries. 
Therefore, our method is useful in improving the hit-rate and enrichment 
factor of SVM while maintaining an equally high hit identification rate as 
other SBVS and LBVS tools. 
 
To further evaluate whether our SVM models predict active compounds rather 
than membership of certain compound families, compound family distribution 
of the predicted active and inactive compounds for the four compound classes 
were analyzed. As shown in Table 3-3, 24.3%, 71.3%, 87.6%, 85.7% of the 
predicted HIV protease inhibitors, DHFR inhibitors, dopamine antagonists, 
and CNS active agents belong to the families that contain no known active 
compound. For those families that contain at least one known active 
compound, >70% of the compounds (>90% in majority cases) in each of these 
families were predicted as inactive compounds by our SVM models. These 
results suggest that our SVM models predict active compounds rather than 
membership to certain compound families. Some of the predicted active 
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compounds not in the family of known active compounds may serve as 
potential “novel” active compounds. Therefore, as in the case shown by an 
earlier study191, SVM methods have certain capacity for predicting novel 
active compounds. 
3.4 Comparative analysis of virtual screening performance of 
our method 
The performance of our method can be more appropriately evaluated by using 
it to develop VS tools and test them based on the same dataset construction 
and testing procedures as those used in other VS methods. In this work, we 
specifically developed additional VS prediction models by using the same 
dataset construction method and same data source of a standard similarity-
based method, the data fusion method48, the performance of both methods 
were then compared by using the same data source. The data fusion method is 
based on Taminoto based similarity searching using multiple reference 
compounds, which have shown good performances for a number of active 
compound groups by using only a small number of training active 
compounds48, and thus is a good reference method for evaluating the 
performance of our method. 
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Table 3-3 Performance of support vector machines virtual screening tools developed in this work for identifying HIV protease 















































































2.986M 2351 0.076% 496 8157 24.3% 0.27% 333 42.6% 1833 78.0% 22.5% 296 
DHFR 
inhibitors 
2.986M 225 0.007% 60 160 71.3% 0.0054% 115 64.4% 118 52.4% 73.8% 10543 
Dopamine 
antagonists 









 We developed three separate HIV protease inhibitor VS tools by using our 
method and datasets of similar sizes and from the same sources as that used by 
the reported studies of the data fusion method48,192. Our training and testing 
datasets were generated from 1,054 HIV protease inhibitors extracted from the 
MDDR database. Based on the training set generation procedure of the data 
fusion method192, three sets of 60, 80 and 100 inhibitors were selected from 
this full set of 1,054 inhibitors as the active compound training sets, from 
which the inactive compound training sets were generated by using our 
method.  Using the same testing method of the data fusion method, the 
performance of the three developed SVM VS tools were evaluated by using 
the remaining 994, 974 and 954 HIV protease inhibitors respectively, which 
showed that 59.5%, 62.2% and 67.3% of these remaining inhibitors were 
correctly identified. The performance of these SVM VS tools is similar to and 
in some cases slightly improved against that of 55.2%~58.0% of the data 
fusion method that used a similar number of training HIV protease 
inhibitors48. This suggests that, by using the equally small active compounds 
as training data, our SVM model is capable of performing at the same level 
and in some cases slightly improved level than that of the data fusion method. 
3.5 Discussion 
The performance of SVM and other ML methods critically depends on the 
diversity of compounds in a training dataset and the appropriate description of 
the compounds. The datasets used in developing ML models described in 
Table 3-1 and in this work are not expected to be fully representative of all of 
the active and inactive compounds. Known inactive compounds, particularly 
those structurally similar to an active compound, may serve to further refine 
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ML models at higher “structural resolutions” than those achievable by using 
only the putative inactive compounds generated from this work. Mining of 
known active compounds and inactive compounds from the literature103 and 
other sources 193,194 is a key to developing more optimally performing ML 
models for VS.  
 
Examination of incorrectly predicted compounds by ML models consistently 
suggests that the currently-used molecular descriptors are insufficient to 
adequately represent some of the compounds that contain complex structural 
or chemical configurations130,149,181. Examples of these agents are those with 
large rigid structures combined with a short flexible hydrophilic tail, 
compounds that contain multi-rings with various hetero atoms such as 
nitrogen, oxygen, sulphur, fluorine and chlorine. Due to the limited coverage 
of the number of bond links in a hetero-atom loop, the currently available 
topological descriptors are not yet capable of describing the special features of 
a complex multi-ring structure that contains multiple hetero atoms. It appears 
that none of the currently-available descriptors are capable of fully 
representing molecules containing a long flexible chain. Therefore, it might be 
helpful to explore different combination of descriptors and to select more 
optimal set of descriptors by using more refined feature selection algorithms 
and parameters130,195. However, indiscriminate use of many existing 
topological descriptors, which are overlapping and redundant to each other, 
may introduce noise as well as extend the coverage of some the aspects of 
these special features. Thus, it may be necessary to introduce new descriptors 
for more appropriately representing these and other special features. 
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3.6 Further perspective 
By using training sets of more diverse spectrum of inactive compounds, the 
hit-rates and enrichment factors of SVM models can be substantially improved 
to the level comparable to and in some cases higher than those of the best 
performing SBVS and LBVS tools reported in the literature. Because of their 
high computing speed and capability for covering highly diverse spectrum 
compounds, SVM and other ML methods can be potentially explored to 
develop useful VS tools to complement other VS methods or to be used as part 




Chapter 4 Evaluation of Virtual Screening by Sparsely 
Distributed Active Compounds 
Virtual screening performance of support vector machines (SVM) depends on 
the diversity of training active and inactive compounds. While diverse inactive 
compounds can be routinely generated, the number and diversity of known 
actives are typically low. In this chapter, we evaluated the performance of 
SVM trained by sparsely distributed actives in six MDDR biological target 
classes composed of high number of known actives of high, intermediate, and 
low structural diversity (muscarinic M1 receptor agonists, NMDA receptor 
antagonists, thrombin inhibitors, HIV protease inhibitors, cephalosporins, and 
rennin inhibitors). 
4.1 Introduction 
As part of the efforts in further developing virtual screening (VS) methods for 
facilitating lead discovery27,37,164,165, support vector machines (SVM)167have 
recently been explored as ligand-based VS (LBVS) tools to complement or to 
be used in combination with structure-based VS (SBVS)37,52-55,65-67,69,168-170 
and other LBVS27 tools. A particular objective for exploring these approaches 
is to overcome several problems that have impeded progress in more extensive 
applications of VS33,37,168. These problems include the vastness and sparse 
nature of chemical space to be searched, limited hit diversity due to the bias of 
training molecules, limited availability of target structures (only 15% of 
known proteins have experimentally-determined 3D structures), complexity 
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and flexibility of target structures, and difficulties in computing binding 
affinity and solvation effects. 
 
SVM is of particular interest because it classifies active compounds based on 
the differentiating physicochemical profiles between active and inactive 
compounds rather than structural similarity to active compounds per se. 
Moreover, SVM does not require the knowledge of target structure and 
activity-related molecular descriptors, and the computation of binding affinity 
and solvation effects. Its fast speed enables efficient search of vast chemical 
space. Some of these advantages have been exhibited by good VS 
performance in screening large compound libraries48,62,108. None-the-less, as in 
the cases of all statistical learning methods, the performance of SVM is 
significantly influenced by the levels of the training active and inactive 
compounds in representing the physicochemical profiles of the remaining 
compounds in the chemical space. 
 
Active compounds (actives) typically occupy small pockets of the chemical 
space. It may be possible to construct a training active dataset to substantially 
represent the properties of the remaining actives by using relatively small 
number of known actives. However, inactive compounds (inactives) generally 
occupy larger portions of the chemical space. A large number of training 
inactives is needed to reach sufficient level of diversity for representing the 
remaining inactives in the chemical space. SVM constructs a hyper-plane in a 
higher dimensional molecular descriptor space to separate actives from 
inactives based on whether or not the molecular descriptor vector of a 
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compound is distributed on the known active side of the hyper-plane. As 
illustrated in Figure 4-1, the position and orientation of the SVM hyper-plane, 
which extends to far regions of the chemical space, can in many cases be 
influenced by inactives distributed remotely from the known actives as well as 
those closely resembling known actives. The level of influence tends to be 
stronger for sparsely distributed known actives and inactives as there is more 
room in the local space for altering the position and orientation of the hyper-
plane. Therefore, highly diverse inactive datasets are typically needed for 
constructing SVM VS models33,108. 
 
 
Figure 4-1 Illustration of the influence of the inactive compounds distributed 
far away from the active compounds on the position and orientation of the 
hyper-plane of support vector machines that separates active and inactive 
compounds. +: active compounds, -: inactive compounds used for constructing 
the first hyper-plane (dashed line), x: additional inactive compounds used for 
constructing the more-refined hyper-plane (solid line). 
 
Highly diverse inactive training datasets can be routinely generated by large-
scale sampling of active compounds of other biological target classes36,48,62,63 
and by using representative compounds from compound families that contain 
no known actives108. In contrast, the diversity and the level of representation 
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of active training datasets are often constrained by the small number of known 
actives sparsely distributed in the active regions of chemical space (active 
regions are defined as regions of chemical space covered by discovered and 
yet-to-be-discovered actives). There is a need to evaluate the VS performance 
of SVM trained by sparse active datasets to determine its capability in 
identifying novel actives from sparsely distributed known actives. 
 
In this work, we examined the VS performance of SVM trained by sparse 
active datasets generated from available active datasets of sufficiently high 
number of known actives and varying degrees of structural diversity. The high 
number of actives in the studied datasets makes it possible to generate 
sufficiently sparse training active datasets, and varying degrees of diversity 
enables objective evaluation of the VS performance of SVM on different 
classes of actives. To facilitate comprehensive analysis and further 
comparative studies, six of the well-studied MDDR biological target classes48 
of high number of actives (983~1,645) of both high, intermediate, low 
structural diversity were used for this study. These classes include muscarinic 
M1 receptor agonists and NMDA receptor antagonists representing high-
diversity, thrombin inhibitors and HIV protease inhibitors representing 
intermediate-diversity, and cephalosporins and rennin inhibitors representing 
low-diversity classes respectively. 
 
Muscarinic M1 receptor agonists are useful for the treatment of Alzheimer's 
disease by improving the performance in cognitive tests in Alzheimer's 
patients196. NMDA receptor antagonists have been explored for 
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neuroprotection197 and the treatment of postoperative pain198. Thrombin 
inhibitors produce anticoagulant effects and have been used as antithrombotic 
agents199. HIV protease inhibitors form an important class of anti-HIV agents 
some of which have been successfully used clinically41. Cephalosporins are in 
clinical development as broad-spectrum antibacterial agents200. Rennin 
inhibitors have shown effectiveness in cardiovascular pharmacotherapy201. 
Because of their diverse therapeutic applications and structural frameworks, 
these compounds are highly useful for testing the performance of SVM as well 
as other methods48. 
 
For each biological target class, two training datasets were generated. A 
regularly sparse active dataset, which contains the same number of actives as 
those in earlier sparse dataset studies33,48 was generated by extracting 100 
actives (representing 6.1%~10.2% of the known actives) scattered in the 
known active region of chemical space. A very sparse active dataset was 
generated by extracting 40 active compounds (representing 2.4%~4.1% of the 
known actives) scattered in the known active region of chemical space. To 
generate a dataset of N number of actives from a larger number actives, all 
actives were clustered into N clusters followed by the extraction of one 
compound from each of these clusters. Putative inactive datasets were 
generated by extracting representative compounds from all compound families 
that contain no known active compound108. Compound families can be 
generated by clustering distinct compounds of chemical databases into groups 




The regularly sparse active datasets were used for facilitating crude estimation 
of the level of performance of our SVM VS tools with respect to those of other 
VS tools such as the data fusion method48 and other methods33  that have been 
frequently developed by using ~100 active compounds. Caution needs to be 
raised about straightforward comparison of these results, which might be 
misleading because the outcome of VS strongly depends on the datasets and 
molecular descriptors used. To further evaluate whether the performance of 
our SVM VS tools are attributed to the SVM classification models or the 
molecular descriptors used, a study was conducted to compare the 
performance our SVM VS tools with that of the Tanimoto-based similarity 
searching method115 using the same datasets and the same molecular 
descriptors.  
 
The yields (percent of testing actives identified as active) of our SVM VS 
tools were estimated by using the remaining 89.7%~97.4% of the known 
actives. The false-hit rates (percent of inactives identified as active) of our 
SVM VS tools were estimated by using the remaining 167K MDDR 
compounds outside the training datasets and by using the 9.997M PubChem 
compounds that exclude the known actives. To further evaluate whether our 
SVM VS tools predict active and inactive compounds rather than membership 
of certain compound families, distribution of the predicted active and inactive 
compounds in the compound families were analyzed. 
 
VS performance may be over-estimated by training datasets that contain 
higher percentages of inactives significantly different from the known actives, 
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because the easily distinguishable features may make VS enrichments 
appearing artificially good202. Therefore, VS performance may be more 
strictly tested by using subsets of inactives that resemble the physicochemical 
properties of the known actives so that enrichment is not simply a separation 
of trivial physicochemical features158. In this work, the performance of our 
SVM VS tools was further evaluated by the subsets of MDDR compounds that 
are similar in physicochemical properties to those of the known actives. 
4.2 Methods 
4.2.1 Construction of active training and testing datasets 
All actives of the six biological target classes are from MDDR, from which we 
obtained 983 muscarinic M1 receptor agonists, 1,510 NMDA receptor 
antagonists, 1,252 thrombin inhibitors, 1,054 HIV protease inhibitors, 1,645 
cephalosporins, and 1,241 rennin inhibitors. The structure of representative 
compounds of these six classes is shown in Figure 4-2. To generate the 
popular-sized sparse and highly sparse active training datasets and the 
corresponding testing datasets, all known actives of each of these classes were 
clustered into 100 and 40 clusters respectively by using a K-means 
method29,189 and molecular descriptors computed from our own software182. 
For each class, the regularly sparse and very sparse active training datasets of 
100 and 40 active compounds were generated by extracting one compound 
from each of the 100 and 40 active clusters respectively. The remaining 
actives were used as the corresponding active testing set. 
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4.2.2 Generation of putative inactive training and testing 
datasets  
Methods in Chapter 3 Section 3.2.2 are used to generate putative inactive 
training and testing datasets. 
 
The classes of muscarinic M1 receptor agonists, NMDA receptor antagonists, 
thrombin inhibitors, HIV protease inhibitors, cephalosporins, and rennin 
inhibitors are distributed in 203, 538, 161, 281, 95, and 138 families 
respectively. Because of the extensive effort in searching the known 
compound libraries for identifying active compounds in these target classes, 
the number of undiscovered “active” families in PubChem database is 
expected to be relatively small, most likely no more than several hundred 
families. The ratio of the discovered and undiscovered “active” families 
(hundreds) and the families that contain no known active compound (~8,993 
based on the current versions of PubChem and MDDR) for these and possibly 
many other target classes is expected to be <15%. Therefore, putative inactive 
training datasets can be generated by extracting a few representative 
compounds of those families that contain no known active compound in the 
active training set, with a maximum possible “wrong” family representation 
rate of <15% even when all of the undiscovered active compounds are 
misplaced into the inactive class, and with the expectation that a substantial 
percentage of active members in the putative “inactive” families can be 
classified as active despite of their family representatives are placed into the 
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Figure 4-2 Structures of the selected muscarinic M1 receptor agonists, NMDA 
receptor antagonists, thrombin inhibitors, HIV protease inhibitors, 
cephalosporins, and rennin inhibitors. PubChem accession number of these 
compounds is given. 
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There are 8790, 8455, 8832, 8712, 8898, and 8855 compound families that 
contain no known muscarinic M1 receptor agonist, NMDA receptor 
antagonist, thrombin inhibitor, HIV protease inhibitor, cephalosporin, and 
rennin inhibitor respectively. Thus the inactive training dataset corresponding 
to each sparse or biased active training dataset was generated by random 
selection of 5~6 representative compounds from each of these “inactive” 
families and those active families with none of their members in the active 
training set. The remaining compounds of the “inactive” families in PubChem 
and MDDR can be used as putative inactive testing sets. It is noted that 
9.6%~68.7% of the active containing families are not covered in the active 
training set, and their representative compounds were deliberately placed into 
the inactive training set as they are not supposed to be known in our study. As 
shown in an earlier study48,49,62 (Chapter 3) and in this work, a substantial 
percentage of the active compounds in these misplaced active containing 
families were predicted as active by our SVM models. Moreover, a small 
percentage of the compounds in these putative inactive datasets are expected 
to be un-reported and un-discovered actives for each of the six biological 
target classes, their presence in these datasets is not expected to significantly 
affect the estimated false positive rate of the developed SVM VS tools. 
 
4.2.3 Molecular descriptors 
A total of 98 important descriptors were chosen from the chemical descriptors 
calculated by our program MODEL which were used in this work. The detail 
about molecular descriptors is explained in Chapter 2 Section 2.2.  
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4.3 Results and discussion 
4.3.1 Comparative analysis of virtual screening performance of 
SVM trained by regularly sparse active datasets 
It is of interest to evaluate the performance of SVM trained from regularly 
sparse active datasets by comparison with literature reported VS performance 
based on similar dataset construction/testing procedures and the same data 
sources. As discussed in the introduction section, the comparison of these 
results should be viewed as providing very crude pictures about the level of 
performance of SVM. In this work, we specifically compared the performance 
of SVM VS tools with those a standard similarity-based method, the data 
fusion method48,192. The data fusion method is based on Tanimoto-based 
similarity searching using multiple reference compounds, which have shown 
good performances for a number of active compound groups by using only a 
small number of ~100 training active compounds48,192, which serves as a good 
reference method for evaluating the performance of SVM. To further evaluate 
whether the performance of SVM is due to the SVM classification models or 
to the molecular descriptors used, SVM results were compared with those of 
the Tanimoto-based similarity searching method based on the same training 
and testing datasets and molecular descriptors. 
 
The statistics of the regularly sparse active datasets, the performance of our 
method, the reported performance of the data fusion method, and the results of 
the Tanimoto-based similarity searching method for the six biological classes 
are given in Table 4-1. As shown in Table 4-1, the percentage of known 
actives in these datasets is in the range of 6.1%~10.2%. The percentage of 
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“active” families (defined as the families that include at least one known 
active compound) covered by these datasets is in the range of 15.4%~67.2% 
with five of the sets below 31.5%. Therefore, these datasets are reasonably 
sparse.   
 
By using the same testing procedure of the data fusion method, the 
performance of the six developed SVM VS tools were evaluated by using the 
remaining 883~1,545 actives and ~167K MDDR compounds of other 
biological target classes. The yields of our SVM VS tools are 26.7%~49.5% 
for the high, 60.0%~67.3% for the intermediate, and 82.1%~91.9% for the low 
diversity classes respectively. The reported yields of the data fusion method 
are 15.7%~46.6% for the high, 44.5%~58.0% for the intermediate, and 
90.4%~94.7% for the low diversity classes respectively48,192. The false-hit 
rates (estimated from the percentage of the ~167K MDDR compounds of 
other biological target classes identified as active) of our SVM VS tools are in 
the range of 1.0%~2.9%. The false-hit rates of data fusion method can be 
deduced as 4% based on the reported top 5% hit selection criterion from 
~150K compounds of other MDDR biological target classes48,192. Compared 
with those of data fusion method, the yields of our SVM VS tools are slightly 
improved for the high and intermediate classes, and the false-hit rates of our 
SVM VS tools are substantially reduced for all three classes. These results 
suggest that, by using the equally small number of active compounds as 
training data, SVM is capable of producing equally good or slightly better 
yields and generalization capability at substantially reduced false-hit rates than 




As shown in Table 4-1, the yields of the Tanimoto-based similarity searching 
method are 9.4%~ 24.2% for the high, 19.0%~27.8% for the intermediate, and 
38.4%~39.3% for the low diversity classes respectively. The false-hit rates are 
in the range of 3.3%~4.4%. Compared to these results, the yields of SVM are 
significantly improved and the false-hit rates of SVM are substantially 
reduced. This suggests that SVM performance is due primarily to the SVM 





Table 4-1 Dataset statistics and the virtual screening performance of support vector machines developed by using regularly sparse 
datasets of 100 active compounds for screening MDDR database. The results are compared with that of the Tanimoto similarity 
searching method using the same dataset and molecular descriptors, and with the reported performance of similarity search 
methods trained by using ~100 active compounds (Ref 48) for identifying muscarinic M1 receptor agonists, NMDA receptor 
antagonists, thrombin inhibitors, HIV protease inhibitors, cephalosporins, and rennin inhibitors. Known “active” chemical 
families refer to chemical families that contain at least one known active compound. Yields and false hit rates are the percent of 
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100 (6.6%) 83 (15.4%) 1410 
(93.4%) 






100 (8.0%) 46 (28.6%) 1152 
(92.0%) 




100 (9.5%) 74 (26.3%) 954 (90.5%) 248 (88.3%) 67.3% 2.9% 51.6%~58.0% 4% 27.8% 4.4% 
Low Cephalosporins 
(1645) [0.501] 
100 (6.1%) 43 (67.2%) 1545 
(93.9%) 




100 (8.1%) 51 (37.0%) 1141 
(91.9%) 




4.3.2 Virtual screening performance of SVM trained by very 
sparse active datasets 
The level of sparseness of the very sparse active datasets for the six biological 
target classes can be measured by the percentage of known actives in these 
training sets and the percentage of “active” families they occupy. As shown in 
Table 4-2, the percentage of known actives in the sparse active training sets is 
in the range of 2.4%~4.7%. The percentage of “active” families covered by the 
sparse active training sets is in the range of 6.7%~42.2% with five of these 
below 22.5%. Therefore, the level of sparseness of the very sparse active 
datasets is significantly higher than those of the regularly sparse active 
datasets. 
 
The SVM VS tools developed by using the very sparse active datasets for 
identifying active compounds of the six biological target classes were tested 
by using three testing sets for each compound class. These testing sets are the 
active testing set for each class, 9.98 million distinct compounds from the 
PubChem, and the remaining 167K MDDR compounds outside the training 
sets of our developed SVM models. The performance of these SVM VS tools 
is given in Table 4-2. In spite of the use of very sparse active training sets of 
<4.7% of the actives covering 6.7%~42.2% of the “active” families, our SVM 
VS tools were able to achieve yields of 17.5%~35.5% for the high, 
23.0%~48.1% for the intermediate, and 70.2%~92.4% for the low diversity 
classes. Therefore, our method appears to have some level of generalization 
capability in identifying a substantial amount of novel active compounds 
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outside the known active chemical families from a very sparse active training 
dataset. 
 
In addition to the exhibition of effective hit selection performance, our SVM 
models appear to show substantially lower false-hit rates. In screening 9.997M 
PubChem compounds that exclude the known actives, without using top-
ranked cut-off or additional filter, our SVM VS tools identified 398~2,336 
compounds as active, representing 0.004%~0.01% of the 9.997M PubChem 
compounds. The estimated false-hit rates in screening 167K MDDR 
compounds of the other biological classes are in the range of 0.5%~1.6%. 
Even though a substantially larger number of compounds (9.997M vs. 
98.4K~2.5M) were screened, these false-hit rates are comparable and in many 
cases better than those of 0.08%~3% by SBVS tools53-55,59,65-67,69,168-170, 
0.1%~5% by other reported ML models48,49,62, 0.16%~82.% by clustering 
methods29 , and 1.15%~26% by pharmacophore models. 
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Table 4-2 Dataset statistics and virtual screening performance of support vector machines developed by using very sparse active 
datasets of 40 active compounds for identifying muscarinic M1 receptor agonists, NMDA receptor antagonists, thrombin 
inhibitors, HIV protease inhibitors, cephalosporins, and rennin inhibitors from PubChem and MDDR databases. Known “active” 


















Active Compounds in 
Training Set 
Active Compounds in 
Testing Set 




























































40 (2.7%) 36 (6.7%) 1470 
(97.3%) 




40 (3.2%) 25 (15.5%) 1212 
(96.8%) 




40 (3.8%) 36 (12.8%) 1014 
(96.2%) 
269 (95.7%) 48.1% 301 (68.7%) 530 (0.005%) 2,658 (1.6%) 
Low Cephalosporins 
(1645) [0.501] 
40 (2.4%) 27 (42.2%) 1605 
(97.6%) 




40 (3.2%) 31 (22.5%) 1201 
(96.8%) 
130 (94.2%) 70.2% 410 (48.6%) 398 (0.004%) 2,220 (1.3%) 
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4.3.3 Evaluation of false-hit rates of SVM against inactives of 
similar molecular descriptors to the known actives 
The subsets of MDDR compounds that are similar in molecular descriptors to 
at least one known active of the six biological target classes were selected by 
using the condition that the Tanimoto coefficient sim(i,j) is ≥ 0.9 with respect 
to at least one known active of each of these classes. A total of 19,495, 38,436, 
32,037, 29,990, 29,127, and 24,166 inactives of similar molecular descriptors 
were collected for the muscarinic M1 receptor agonist, NMDA receptor 
antagonist, thrombin inhibitor, HIV protease inhibitor, cephalosporin, and 
rennin inhibitor classes respectively. Each of these six sets of inactives were 
used as the testing sets for evaluating the false-hit rates of our developed SVM 
VS tools against similarity compounds.  
 
As shown in Table 4-3, against these similarity datasets, the false-hit rates of 
our SVM VS tools developed by using regularly sparse and very sparse active 
datasets are in the range of 4.6%~8.3% and 2.6%~6.3% respectively. 
Compared to the ranges of hit rates of 1.0%~2.9% and 0.5%~1.6% against the 
full set of the ~167K MDDR compounds of other biological target classes, our 
developed SVM VS tools appear to show fairly good performance in 
distinguishing the actives from the inactives that resemble the 
physicochemical properties of the known actives. 
 
4.3.4 Evaluation of SVM identified false hits 
Some of the false hits are known inhibitors that share structural frameworks 
with those of the studied biological target class. For instance, a number of 
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SVM identified “false” hits of HIV protease inhibitors are known rennin 
inhibitors. Some of the HIV protease inhibitors have been designed based on 
the transition state analogues of renin inhibitors203. Many of the SVM 
identified false hits of thrombin inhibitors are known peptidomimetic 
inhibitors of renin, HIV protease, farnesyltransferase, and trypsin. 
Peptidomimetic inhibitors arising from similar structural frameworks have 
been designed for renin, thrombin, HIV protease, Ras farnesyltransferase, and 
various other proteases204. Therefore, some of the false hits may partly arise 
from the mis-identification of compounds of similar structural frameworks. It 
cannot be ruled out that some of them may exhibit weak inhibitory activities 
due to the similar structural frameworks and thus were “correctly” identified 
by our SVM VS tools. 
 
Examination of the false hits identified by SVM and other machine learning 
methods consistently suggests that the currently-used molecular descriptors 
are insufficient to adequately represent some of the compounds that contain 
complex structural or chemical configurations130,149,181. Examples of these 
agents are those with large rigid structure combined with a short flexible 
hydrophilic tail, compounds that contain multi-rings with various hetero atoms 
such as nitrogen, oxygen, sulphur, fluorine and chlorine. Due to the limited 
coverage of the number of bond links in a hetero-atom loop, the currently 
available topological descriptors are not yet capable of describing the special 
features of a complex multi-ring structure that contains multiple hetero atoms. 
It appears that none of the currently-available descriptors are capable of fully 
representing molecules containing a long flexible chain. Therefore, it might be 
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helpful to explore different combination of descriptors and to select more 
optimal set of descriptors by using more refined feature selection algorithms 
and parameters130,195. However, indiscriminate use of many existing 
topological descriptors, which are overlapping and redundant to each other, 
may introduce noise as well as extending the coverage of some the aspects of 
these special features. Thus, it may be necessary to introduce new descriptors 
for more appropriately representing these and other special features. 
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Table 4-3 Evaluation of support vector machines virtual screening tools for identifying muscarinic M1 receptor agonists, NMDA 
receptor antagonists, thrombin inhibitors, HIV protease inhibitors, cephalosporins, and rennin inhibitors against the subset of 
inactive MDDR compounds that are similar to at least one known active compound in each respective active compound class. 
Similarity is defined by Tanimoto coefficient ≥0.9, which is computed by using molecular descriptors. The yields are given in 
Table 4-1 and Table 4-2 respectively. 
 
Compound Diversity 
Category Defined in Ref 
48 
Compound Biological 
Target Class (No of 
compounds)  
No and Percent of Active 
Compounds in Training 
Set 
No of Inactive Compounds 
Similar to an Active 
Compound  
(Testing Set) 
SVM Virtual Screening Performance 
No of Inactive 
Compounds Predicted as 
Active 
False Hit Rate 
High Muscarinic M1 receptor 
agonists (983)  
40 (4.1%) 19,495 531 4.4% 
100 (10.2%) 1,068 7.8% 
NMDA receptor antagonists 
(1510)  
40 (2.7%) 38,436 729 2.6% 
100(6.6%) 1,349 4.6% 
Intermediate Thrombin inhibitors (1252)  40 (3.2%) 32,037 1,535 5.7% 
100(8.0%) 1,267 6.4% 
HIV protease inhibitors 
(1054)  
40 (3.8%) 29,990 603 3.3% 
100(9.5%) 1,398 6.4% 
Low Cephalosporins (1645)  40 (2.4%) 29,127 181 5.8% 
100(6.1%) 612 7.6% 
Rennin inhibitors (1241) 40 (3.2%) 24,166 637 6.3% 




4.3.5 Does SVM select active compounds or membership of 
compound families? 
To further evaluate whether our SVM VS tools identify active compounds 
rather than membership of certain compound families, Compound family 
distribution of the identified actives and inactives for the six biological target 
classes were analyzed. As shown in Table 4-2, 40.1%, 64.2%, 57.0%, 68.7%, 
13.8%, and 48.6% of the identified muscarinic M1 receptor agonists, NMDA 
receptor antagonists, thrombin inhibitors, HIV protease inhibitors, 
cephalosporins, and rennin inhibitors belong to the families that contain no 
known active. For those families that contain at least one known active, >70% 
of the compounds (>90% in majority cases) in each of these families were 
predicted as inactive by our SVM VS tools. These results suggest that our 
SVM VS tools identify active compounds rather than membership to certain 
compound families. Some of the identified actives not in the family of known 
active compounds may serve as potential “novel” active compounds. 
Therefore, as in the case shown by earlier studies108,191, SVM has certain 
capacity for identifying novel active compounds from sparse as well as 
regular-sized active datasets. 
4.4 Further perspective 
SVM VS tools developed by using highly sparse active datasets show some 
level of capability in identifying novel active compounds at comparable and in 
many cases substantially lower false-hit rates than those of typical SBVS and 
LBVS tools reported in the literatures. The performance of SVM is 
significantly better than that of Tanimoto-based similarity search method 
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based on the same datasets and molecular descriptors, suggesting that the VS 
performance of SVM is primarily due to SVM classification models rather 
than the molecular descriptors used. Because of their high computing speed 
and generalization capability for covering highly diverse spectrum 
compounds, SVM can be potentially explored to develop useful VS tools to 
complement other VS methods or to be used as part of integrated VS tools in 





Chapter 5 Virtual Screening of Selective Kinase 
Inhibitors 
High performance virtual screening tools we built in Chapter 3 can be applied 
for searching novel ligands for many targets whose ligands are available. The 
aim of this chapter is to investigate the applicability of our virtual screening 
method in predicting and searching potential c-Src (Section 5.1) and VEGFR-
2 (Section 5.2) selective kinase inhibitors. c-Src and VEGFR-2 are two 
important kinases that play various roles in tumour progression, invasion, 
metastasis, angiogenesis and survival. New inhibitors for c-Src and VEGFR-2 
are necessary for pharmaceutical research of cancer treatment. 
5.1 Virtual screening of c-Src kinase inhibitors 
5.1.1 c-Src, c-Src inhibitors and cancer 
Src promotes tumour invasion and metastasis, facilitates VEGF-mediated 
angiogenesis and survival in endothelial cells, and enhances growth factor 
driven proliferation in fibroblasts205. It is one of the multiple kinase targets of 
a number of multi-target kinase inhibitors effective in the clinical treatment of 
leukemia and in clinical trials of other cancers86,206,207. The successes and 
problems of these inhibitors have raised significant interest and efforts in 
discovering new Src inhibitors208-210. Several in-silico methods have been used 
for facilitating the search and design of Src inhibitors, which include 




While these in-silico methods have shown impressive capability in the 
identification of potential Src inhibitors, their applications may be affected by 
such problems as the vastness and sparse nature of chemical space that needs 
to be searched, complexity and flexibility of target structures, difficulties in 
accurately estimating binding affinity and solvation effects, and limited 
diversity of training active compounds33,37,168. It is desirable to explore other 
in-silico methods that complement these methods by expanded coverage of 
chemical space, increased screening speed, and reduced false-hit rates without 
necessarily relying on the modelling of target structural flexibility, binding 
affinity and salvation effects.  
 
In this work, we developed a SVM VS model for identifying Src inhibitors, 
and evaluated its performance by both 5-fold cross validation test and large 
compound database screening test. In 5-fold cross validation test, a dataset of 
Src inhibitors and non-inhibitors was randomly divided into 5 groups of 
approximately equal size, with 4 groups used for training a SVM VS tool and 
1 group used for testing it, and the test process is repeated for all 5 possible 
compositions to derive an average VS performance. In large database 
screening test, a SVM VS tool was developed by using Src inhibitors 
published before 2008, its yield (percent of known inhibitors identified as 
virtual-hits) was estimated by using Src inhibitors reported since 2008 and not 
included in the training datasets, virtual-hit rate and false-hit rate in searching 
large libraries were evaluated by using 13.56M PubChem, 168K MDDR, and 
9,305 MDDR compounds similar in structural and physicochemical properties 




PubChem and MDDR contain high percentages of inactive compounds 
significantly different from the known Src inhibitors, and the easily 
distinguishable features may make VS enrichments artificially good202. 
Therefore, VS performance may be more strictly tested by using subsets of 
compounds that resemble the physicochemical properties of the known Src 
inhibitors so that enrichment is not simply a separation of trivial 
physicochemical features158. To further evaluate whether our SVM VS tool 
predict Src inhibitors and non-inhibitors rather than membership of certain 
compound families, distribution of the predicted active and inactive 
compounds in the compound families were analyzed. 
5.1.2 Virtual screening model development 
5.1.2.1 Compound collections and construction of training and 
testing datasets 
We collected 1,020 Src inhibitors, with IC50<50M, from the literatures213-217 
and the BindingDB database110. Our collected Src inhibitors are distributed in 
288 families. The inhibitor selection criterion of IC50<50M was used 
because it covers most of the reported HTS and VS hits218. The structures of 
representative Src inhibitors are shown in Figure 5-1. As few non-inhibitors 
have been reported, putative non-inhibitors were generated by using our 
method for generating putative inactive compounds108,219 (please refer to 
Chapter 3 Section 3.2.2).  
 
In the database screening test, 60.1% of families that contain Src inhibitors 
reported since 2008 are not covered by the Src inhibitor training dataset 
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(inhibitors reported before 2008), and the representative compounds of these 
families were deliberately placed into the inactive training sets as these 
inhibitors are not supposed to be known in our study. As shown in earlier 
studies108,219 and in this work, a substantial percentage of the inhibitors in 
these misplaced inhibitor-containing “non-inhibitor” families were predicted 
as inhibitors by our SVM VS tool. Moreover, a small percentage of the 
compounds in these putative non-inhibitor datasets are expected to be un-
reported and un-discovered inhibitors, their presence in these datasets is not 
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5.1.2.2 Molecular descriptors and computational model 
A total of 98 important descriptors were chosen from the chemical descriptors 
calculated by our program MODEL which were used in this work. The details 
of molecular descriptors are explained in Chapter 2 Section 2.2. 
Computational model for virtual screening is developed by using SVM. 
 
5.1.3 Results and Discussion 
5.1.3.1 Performance of SVM identification of Src inhibitors 
based on 5-fold cross validation test 
Table 5-1 shows the 5-fold cross validation test results of SVM identification 
of Src inhibitors and putative non-inhibitors. The inhibitor and non-inhibitor 
prediction accuracies are 87.8%~93.1% and 99.75%~99.88% respectively. 
The overall prediction accuracy Q and Matthews correlation coefficient C are 
99.61%~99.77% and 0.759~0.857 respectively. The inhibitor accuracies of our 
SVM are comparable to or slightly better than the reported accuracies of 
58.3%~67.3% for protein kinase C inhibitors by SVM-RBF and CKD 
methods36, 83% for Lck inhibitors by SVM method218, and 74%~87% for 
inhibitors of any of the 8 kinases (3 Ser/Thr and 5 Tyr kinases) by SVM, 
ANN, GA/kNN, and RP methods94. The non-inhibitor accuracies are 
comparable to the value of 99.9% for Lck inhibitors218 and substantially better 
than the typical values of 77%~96% of other studies36,94. Caution needs to be 
exercised about straightforward comparison of these results, which might be 
misleading because the outcome of VS strongly depends on the datasets and 
molecular descriptors used.  Based on these rough comparisons, SVM appears 
to show good capability in identifying Src inhibitors at low false-hit rates. 
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Similar prediction accuracies were also found from two additional 5-fold cross 
validation studies conducted by using training-testing sets separately generated 
from different random number seed parameters. 
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Table 5-1 Performance of support vector machines for identifying Src 
















TN FP SP(%)   
1 816/204 189 15 92.65% 51966/12992 12959 33 99.75% 99.64% 0.786 
2 816/204 184 20 90.20% 51966/12992 12975 17 99.87% 99.72% 0.823 




12965 27 99.79% 99.61% 0.759 
4 816/204 190 14 93.14% 51967/12991 12959 32 99.75% 99.65% 0.794 
5 816/204 190 14 93.14% 51967/12991 12975 16 99.88% 99.77% 0.857 
average    91.47%    99.81% 99.68% 0.804 
SD    0.0212    0.000557 0.000605 0.0336
SE    0.0095    0.00025 0.00027 0.0150
 
5.1.3.2 Virtual screening performance of SVM in searching Src 
inhibitors from large compound libraries 
As outlined in the methods section, we developed a SVM VS tool for 
searching Src inhibitors from large were developed by using Src kinases 
reported before 2008. The VS performance of SVM in identifying Src 
inhibitors reported since 2008 and in searching MDDR and PubChem 
databases is summarised in Table 5-2. The yield in searching Src inhibitors 
reported since 2008 is 66.2%, which is comparable to the reported 50%~94% 
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yields of various VS tools220. Strictly speaking, direct comparison of the 
reported performances of these VS tools is inappropriate because of the 
differences in the type, composition and diversity of compounds screened, and 
in the molecular descriptors, VS tools and their parameters used. The 
comparison cannot go beyond the statistics of accuracies.  
Table 5-2 Virtual screening performance of support vector machines for 




Number of Inhibitors 1020 
Number of Chemical Families Covered by Inhibitors 288 
Inhibitors in Testing 
Set 
Number of Inhibitors 133 
Number of Chemical Families Covered by Inhibitors 65 
Percent of Inhibitors in Chemical Families Covered by 





Number and Percent of Identified  True Inhibitors 
Outside Training Chemical Families 
43 (32.3%) 
Number and Percent of 13.56M PubChemCompounds 
Identified as Inhibitors 
44,843 
(0.33%) 
Number and Percent of the 168K MDDR Compounds 
Identified as Inhibitors 
1,496 
(0.89%) 
Number and Percent of the 9,305 MDDR Compounds 
Similar to the Known Inhibitors Identified as Inhibitors
719 (7.73%) 
 
We also evaluated virtual-hit rates and false-hit rates of SVM in screening 
compounds that resemble the structural and physicochemical properties of the 
known Src inhibitors by using 9,305 MDDR compounds similar to an Src 
inhibitor in the training dataset. Similarity was defined by Tanimoto similarity 
coefficient ≥0.9 between a MDDR compound and its closest inhibitor219. SVM 
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identified 719 virtual-hits from these 9,305 MDDR similarity compounds 
(virtual-hit rate 7.73%), which suggests that SVM has some level of capability 
in distinguishing Src inhibitors from non-inhibitor similarity compounds. 
Significantly lower virtual-hit rates and thus false-hit rates were found in 
screening large libraries of 168K MDDR and 13.56M PubChem compounds. 
The numbers of virtual-hits and virtual-hit rates in screening 168K MDDR 
compounds are 1,496 and 0.89% respectively. The numbers of virtual-hits and 
virtual-hit rates in screening 13.56M PubChem compounds are 44,843 and 
0.33% respectively.  
 
Substantial percentages of the MDDR virtual-hits belong to the classes of 
antineoplastic, tyrosine-specific protein kinase inhibitors, signal transduction 
inhibitors, antiangiogenic, and antiarthritic (Table 5-3, details in next section). 
As some of these virtual-hits may be true Src inhibitors, the false-hit rate of 
our SVM is at most equal to and likely less than the virtual-hit rate. Hence the 
false-hit rate is <7.73% in screening 9,305 MDDR similarity compounds, 
<0.89% in screening 168K MDDR compounds, and <0.33% in screening 
13.56M PubChem compounds, which are comparable and in some cases better 
than the reported false-hit rates of 0.0054%~8.3% of SVM89,219, 0.08%~3% of 
structure-based methods, 0.1%~5% by other machine learning methods, 





5.1.3.3 Evaluation of SVM identified MDDR virtual-hits 
SVM identified MDDR virtual-hits were evaluated based on the known 
biological or therapeutic target classes specified in MDDR. Table 5-3 gives 
the MDDR classes that contain higher percentage (≥3%) of SVM virtual-hits 
and the percentage values. We found that 623 (41.6%) of the 1,496 virtual-hits 
belong to the antineoplastic class, which represent 2.9% of the 21,557 MDDR 
compounds in the class. In particular, 231 (15.4%) of the virtual-hits belong to 
the tyrosine-specific protein kinase inhibitor class, which represent 19.6% of 
the 1,181 MDDR compounds in the class. Moreover, 194 (13.0%) and 75 
(5.0%) of the virtual-hits belong to the signal transduction inhibitor and 
antiangiogenic classes, representing 9.5% and 4.6% of the 2,037 and 1,629 
members in these classes respectively. Therefore, many of the SVM virtual-
hits are antineoplastic compounds that inhibit tyrosine kinases and possibly 
other kinases involved in signal transduction and angiogensis pathways. While 
some of these kinase inhibitors might be true Src inhibitors, a significant 
percentage of them are expected to arise from false selection of inhibitors of 




Table 5-3 MDDR classes that contain higher percentage (≥3%) of virtual-hits 
identified by SVMs in screening 168K MDDR compounds for Src inhibitors. 
The total number of SVM identified virtual hits is 1,496. 
 
MDDR Classes that Contain 
Higher Percentage (≥3%) of 
Virtual Hits  
No of Virtual Hits 
in Class 
Percentage of Class 
Members Selected as 
Virtual Hits 
Antineoplastic 623 (41.6%) 2.9% 
Tyrosine-Specific Protein Kinase 
Inhibitor 
231 (15.4%) 19.6% 
Signal Transduction Inhibitor 194 (13.0%) 9.5% 
Antiarthritic 176 (11.8%) 1.5% 
Antiallergic/Antiasthmatic 83 (5.5%) 0.8% 
Antihypertensive 76 (5.1%) 0.7% 
Antiangiogenic 75 (5.0%) 4.6% 
Treatment for Osteoporosis 55 (3.68%) 2.2% 
Antidepressant 49 (3.27%) 0.8% 
 
176 (11.8%) of the SVM virtual-hits belong to the antiarthritic class. A 
primary feature of rheumatoid arthritis in synovial tissues is the abnormal 
stimulation of fibrin deposition, angiogenesis and proinflammatory processes, 
which are promoted by thrombin increased IL-6 production via the PAR1 
receptor/PI-PLC/PKC alpha/c-Src/NF-kappaB and p300 signaling 
pathways221. Therefore, Src inhibitors may have some effects against arthritis 
via interference with some of these processes. Moreover, several other kinases 
have been implicated in arthritis. An Abl inhibitor Gleevec has been reported 
to be effective in treatment of arthritis, which is probably due to its inhibition 
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of other related kinases such as c-kit and PDGFR222. EGFR-like receptor 
stimulates synovial cells and its elevated activities may be involved in the 
pathogenesis of rheumatoid arthritis89. VEGF has been related to such 
autoimmune diseases as systemic lupus erythematosus, rheumatoid arthritis, 
and multiple sclerosis223. FGFR may partly mediates osteoarthritis224. PDGF-
like factors stimulates the proliferative and invasive phenotype of rheumatoid 
arthritis synovial connective tissue cells225. Lck inhibition leads to 
immunosuppression and has been explored for the treatment of rheumatoid 
arthritis and asthma226. Therefore, some of the SVM virtual-hits in the 
antiarthritic class may be inhibitors of these kinases or their kinase-likes 
capable of producing antiarthritic activities.  
 
Moreover, 83 (5.5%), 76 (5.1%), 55 (3.7%) and 49 (3.3%) of the SVM virtual 
hits are in the antiallergic/antiasthmatic, antihypertensive, osteoporosis 
treatment and antidepressant classes respectively. Src or Src family kinases 
have been implicated in and the respective inhibitors have shown observable 
effects against these diseases. For instance, Src family kinases and lipid 
mediators have been found to partly control allergic inflammation227. 
Inhibition of Src family kinase-dependent signaling cascades in mast cells may 
exert anti-allergic activity228. Up-regulation of Src signaling has been 
suggested to be important in the profibrotic and proinflammatory actions of 
aldosterone in a genetic model of hypertension, which can be significantly 
reduced by mineralocorticoid receptor blocker and Src inhibitor229. Src 
signalling pathways play critical roles in osteoclasts and osteoblasts, and Src 
inhibitors have been developed as therapeutic agents for bone diseases230,231. 
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Src-family protein tyrosine kinases negatively regulate cerebellar long-term 
depression, which can be recovered by the application of Src-family protein 
tyrosine kinase inhibitors232. Therefore, some of the SVM virtual hits in these 
four MDDR classes may be Src inhibitors or Src family kinase inhibitors 
capable of regulating allergic inflammation, hypertension, osteoporosis and 
depression respectively. 
 
5.1.3.4 Comparison of Virtual Screening Performance of SVM 
with Tanimoto-Based Similarity Searching Method 
To evaluate whether the performance of SVM is due to the SVM classification 
models or to the molecular descriptors used, SVM results were compared with 
those of the Tanimoto-based similarity searching method (please refer to 
Chapter 2 Section 2.3.4) based on the same molecular descriptors, training 
dataset of Src inhibitors reported before 2008, and the testing dataset of Src 
inhibitors reported since 2008 and 168K MDDR compounds. The yield and 
maximum possible false-hit rate of the Tanimoto-based similarity searching 
method is 36.84% and 5.54% respectively. Compared to these results, the 
yield of SVM is smaller than but still comparable to that of the Tanimoto-
based similarity searching method, and the false-hit rate of SVM is 
significantly reduced by ~10 fold. This suggests that SVM performance is due 
primarily to the SVM classification models rather than the molecular 
descriptors used, and SVM is capable of achieving comparable yield at 





5.1.3.5 Does SVM select Src inhibitors or membership of 
compound families? 
To further evaluate whether SVM identifies Src inhibitors rather than 
membership of certain compound families, Compound family distribution of 
the identified Src inhibitors and non-inhibitors were analyzed. 48.9% of the 
identified inhibitors belong to the families that contain no known Src 
inhibitors. For those families that contain at least one known Src inhibitor, 
>70% of the compounds (>90% in majority cases) in each of these families 
were predicted as non-inhibitor by SVM. These results suggest that SVM 
identify Src inhibitors rather than membership to certain compound families. 
Some of the identified inhibitors not in the family of known inhibitors may 
serve as potential “novel” Src inhibitors. Therefore, as in the case shown by 
earlier studies108, SVM has certain capacity for identifying novel active 
compounds from sparse as well as regular-sized active datasets. 
 
5.1.4 Further perspective 
Our study suggested that SVM is capable of identifying Src inhibitors at 
comparable yield and in many cases substantially lower false-hit rate than 
those of typical VS tools reported in the literatures. It can be used for 
searching large compound libraries at sizes comparable to the 13.56M 
PubChem and 168K MDDR compounds at low false-hit rates without the need 
to define an applicability domain, i.e. it has a broad applicability domain that 
covers the whole chemical space defined by the current versions of PubChem 
and MDDR databases. The performance of SVM is substantially improved 
against Tanimoto-based similarity search method based on the same datasets 
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and molecular descriptors, suggesting that the VS performance of SVM is 
primarily due to SVM classification models rather than the molecular 
descriptors used. Because of its high computing speed and generalization 
capability for covering highly diverse spectrum compounds, SVM can be 
potentially explored to develop useful VS tools to complement other VS 
methods or to be used as part of integrated VS tools in facilitating the 
discovery of Src inhibitors and other active compounds65,69,71. 
5.2 Virtual screening of VEGFR-2 kinase inhibitors 
5.2.1 VEGFR, VEGFR inhibitors and cancer 
VEGFR regulates angiogenesis, growth, migration and survival233. There are 3 
main VEGFR subtypes, VEGFR-2 mediates almost all of the known cellular 
responses to VEGF, VEGFR-1 modulates VEGFR-2 signaling and acts as a 
dummy/decoy receptor, and VEGFR-3 mediates lymphangiogenesis in 
response to VEGF-C and VEGF-D233. VEGFR inhibitors have been 
successfully used for cancer treatments86,234. While increasing number of 
VEGFR inhibitors have been developed and tested, several problems limit the 
scope of their practical applications. These problems include increased toxicity 
partly due to the targeting of multiple kinases, acquired resistances, and 
reduced tumor responses (VEGFR inhibitors can cause extensive tumor 
necrosis without a marked decrease in tumor size) 235. Moreover, on-target 
toxicity against specific VEGFR subtypes in various tissues is also a 
significant problem for the applications of VEGFR inhibitors236.  The 
successes of VEGFR inhibitors and the encountered problems have led to 




In-silico methods such as pharmacophore237, QSAR63,238,239, fragment-based 
method240, molecular docking241,242, and their combinations237,239 have been 
used for facilitating the search and design of VEGFR inhibitors, which have 
shown impressive capability in the identification of potential VEGFR 
inhibitors. In this work, SVM was tested for its capability in searching 
VEGFR-2 inhibitors from large compound libraries. Our focus on inhibitors of 
VEGFR-2 subtype was based on the availability of reported inhibitors of the 
subtype and the consideration that VEGFR-2 mediates almost all of the known 
cellular responses to VEGF233. The performance of SVM was evaluated by 
both 5-fold cross validation test and large database screening test. In 5-fold 
cross validation test, VEGFR-2 inhibitors and non-inhibitors was randomly 
divided into 5 groups of approximately equal size, with 4 groups used for 
training a SVM VS tool and 1 group used for testing it, and the test process is 
repeated for all 5 possible compositions to derive an average VS performance. 
In large database screening test, SVM was developed by using VEGFR-2 
inhibitors published before 2008, its yield (percent of known inhibitors 
identified as virtual-hits) was estimated by using VEGFR-2 inhibitors reported 
since 2008 and not included in the training datasets, virtual-hit rate and false-
hit rate of the SVM in searching large libraries were evaluated by using 
13.56M PubChem, 168K MDDR, and 13,872 MDDR compounds similar in 
structural and physicochemical properties to the known VEGFR-2 inhibitors.  
 
Databases such as PubChem and MDDR contain high percentages of inactive 
compounds significantly different from VEGFR-2 inhibitors, and the easily 
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distinguishable features may make VS enrichments artificially good202. 
Therefore, VS performance may be more strictly tested by using subsets of 
compounds that resemble the physicochemical properties of the known 
VEGFR-2 inhibitors so that enrichment is not simply a separation of trivial 
physicochemical features158. To further evaluate whether SVM predict 
VEGFR-2 inhibitors and non-inhibitors rather than membership of certain 
compound families, distribution of the predicted active and inactive 
compounds in the compound families were analyzed. Moreover, VS 
performance of SVM for screening MDDR compounds was compared with 
that of Tanimoto similarity search method on the same molecular descriptors, 
training dataset to determine whether the performance of SVM is due to the 
SVM classification models or to the molecular descriptors used. 
 
5.2.2 Virtual screening model development 
5.2.2.1 Compound collection, training and testing datasets, 
molecular descriptors 
Using the inhibitor selection criterion of IC50<10M, which covers most of 
the reported HTS and VS hits243,244,  we collected 1,293 VEGFR-2 inhibitors 
regardless of their activities against other VEGFR subtypes from the 
literatures245-255 and the BindingDB database110. The structures of 
representative VEGFR-2 inhibitors are shown in Figure 5-2. Our collected 
VEGFR-2 inhibitors are distributed in 433 families. As few non-inhibitors 
have been reported, putative non-inhibitors were generated by using our 
method for generating putative inactive compounds108,219 (please refer to 
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Figure 5-2 The structures of representative VEGFR-2 inhibitors 
 
 
In conducting large database screening test, 1293 VEGFR-2 inhibitors 
reported before 2008 were used as a training dataset for developing SVM and 
372 VEGFR-2 inhibitors reported since 2008 were used as an independent 
testing dataset for testing SVM. Only 27.6% of the families that contain 
VEGFR-2 inhibitors reported since 2008 are covered in the families that 
contain at least one VEGFR-2 inhibitor reported before 2008, and the 
representative compounds of these families were deliberately placed into the 
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inactive training sets as these inhibitors are not supposed to be known in our 
study. As shown in earlier studies256 and in this work, a substantial percentage 
of the inhibitors in these misplaced inhibitor-containing “non-inhibitor” 
families were predicted as inhibitors by SVM. Moreover, a small percentage 
of the compounds in these putative non-inhibitor datasets are expected to be 
un-reported and un-discovered inhibitors, their presence in these datasets is 
not expected to significantly affect the estimated false hit rate of SVM. 
 
5.2.2.2 Molecular Descriptors and computational model 
A total of 98 important descriptors were chosen from the chemical descriptors 
calculated by our program MODEL which were used in this work. The detail 
about molecular descriptors is explained in Chapter 2 Section 2.2. 
Computational model for virtual screening is developed by using SVM. 
 
5.2.3 Results and Discussion 
5.2.3.1 VEGFR-2 Inhibitor prediction Performance of SVM 
evaluated by 5-fold cross validation test 
Table 5-4 gives the 5-fold cross validation test results of SVM in identifying 
VEGFR-2 inhibitors and non-inhibitors. The accuracies for predicting 
inhibitors and non-inhibitors are 86.0%~90.0% and 99.62%~99.73% 
respectively. The overall prediction accuracy Q and Matthews correlation 
coefficient C are 99.40%~99.47% and 0.7236~0.7548 respectively. The 
inhibitor accuracies of our SVM are comparable to or better than the reported 
accuracies of 58.3%~67.3% for protein kinase C inhibitors by SVM-RBF and 
CKD methods36, 83% for Lck inhibitors by SVM method218, and 74%~87% 
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for inhibitors of any of the 8 kinases (3 Ser/Thr and 5 Tyr kinases) by SVM, 
ANN, GA/kNN, and RP methods94. The non-inhibitor accuracies are 
comparable to the value of 99.9% for Lck inhibitors218 and substantially better 
than the typical values of 77%~96% of other studies36,94. These are consistent 
with the result of a study of the comparison of SVM with 16 classification 
methods and 9 regression methods, which has shown that SVMs showed 
mostly good performances both on classification and regression tasks but other 
methods proved to be very competitive256. Caution needs to be raised about 
straightforward comparison of these results, which might be misleading 
because the outcome of VS strongly depends on the datasets and molecular 
descriptors used.  Based on these rough comparisons, SVM appears to show 
good prediction capability in identifying VEGFR-2 inhibitors at low false-hit 
rates. Similar prediction accuracies are also found from two additional 5-fold 
cross validation studies conducted by using training-testing sets separately 
generated from different random number seed parameters. 
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Table 5-4 Performance of support vector machines for identifying VEGFR-2 
















TN FP SP(%)   
1 1034/259 227 32 87.64% 51038/12760 12714 46 99.64% 99.40% 0.7236
2 1034/259 231 28 89.19% 51038/12760 12712 48 99.62% 99.42% 0.7334




12715 43 99.66% 99.47% 0.7548
4 1035/258 229 41 88.76% 51039/12759 12718 41 99.68% 99.46% 0.7481
5 1035/258 222 36 86.05% 51039/12759 12725 34 99.73% 99.46% 0.7415
Average    88.32%    99.67% 99.44% 0.7403
SD    0.0152     0.000422 0.000303 0.0122
SE    0.0068    0.000189 0.000136 0.0055
 
5.2.3.2 Virtual screening performance of SVM in searching 
VEGFR-2 inhibitors from large compound libraries 
A SVM in searching VEGFR-2 inhibitors from large libraries was developed 
by using VEGFR-2 inhibitors reported before 2008. The VS performance of 
this SVM in identifying VEGFR-2 inhibitors reported since 2008 and in 
searching MDDR and PubChem databases is summarised in Table 5-5. The 
yield in searching VEGFR-2 inhibitors reported since 2008 is 57.3%, which is 
comparable to the reported 50%~94% yields of various VS tools220. Strictly 
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speaking, direct comparison of the reported performances of these VS tools is 
inappropriate because of the differences in the type, composition and diversity 
of compounds screened, and in the molecular descriptors, VS tools and their 
parameters used. The comparison cannot go beyond the statistics of accuracies 
as the reports are not detailed enough to address questions of whether all 
methods detect the same hit.  
Table 5-5 Virtual screening performance of support vector machines for 




No of Inhibitors 1293 
No of Chemical Families Covered by Inhibitors 433 
Inhibitors in Testing 
Dataset 
No of Inhibitors 372 
No of Chemical Families Covered by Inhibitors 152 
Percent of Inhibitors in Chemical Families Covered by 





No and Percent of Identified  True Inhibitors Outside 
Training Chemical Families 
114 (53.5%) 
No and Percent of 13.56M PubChemCompounds 
Identified as Inhibitors 
89,572 
(0.66%) 
No and Percent of the 168K MDDR Compounds 
Identified as Inhibitors 
2,717 
(1.62%) 
No and Percent of the 13,872 MDDR Compounds 




Virtual-hit rates and false-hit rates of SVM in screening compounds that 
resemble the structural and physicochemical properties of the VEGFR-2 
inhibitors were evaluated by using 13,872 MDDR compounds similar to a 
VEGFR-2 inhibitor in the training dataset. Similarity was defined by 
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Tanimoto similarity coefficient ≥0.9 between a MDDR compound and its 
closest dual-inhibitor124. SVM identified 1,714 virtual-hits from these 13,872 
MDDR similarity compounds (virtual-hit rate 12.4%), which suggests that 
SVM has some level of capability in distinguishing VEGFR-2 inhibitors from 
similarity non-inhibitors. Significantly lower virtual-hit rates and thus false-hit 
rates were found in screening large libraries of 168K MDDR and 13.56M 
PubChem compounds. The numbers of virtual-hits and virtual-hit rates in 
screening 168K MDDR compounds are 2,717 and 1.62% respectively. The 
numbers of virtual-hits and virtual-hit rates in screening 3.56M PubChem 
compounds are 89,572 and 0.66% respectively.  
 
Many of the 2,717 MDDR virtual-hits belong to the classes of antineoplastic 
(45.3%), tyrosine-specific protein kinase inhibitor (12.7%), signal transduction 
inhibitor (12.7%), antiarthritic (11.0%), and antiangiogenic (9.3%), 
antihypertensive (5.1%), antiallergic/antiasthmatic (4.3%), and antidepressant 
(3.4%) (Table 5-6, details in next section). As some of these virtual-hits may 
be true VEGFR inhibitors, the false-hit rate of our SVM is at most equal to 
and likely less than the virtual-hit rate. Hence the false-hit rate is ≤12.36% in 
screening 13,872 MDDR similarity compounds, ≤1.62% in screening 168K 
MDDR compounds, and ≤0.66% in screening 13.56M PubChem compounds, 
which are comparable and in some cases better than the reported false-hit rates 
of 0.0054%~8.3% of SVM257, 0.08%~3% of structure-based methods, 
0.1%~5% by other machine learning methods, 0.16%~8.2% by clustering 
methods, and 1.15%~26% by pharmacophore models258. 
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Table 5-6 MDDR classes that contain higher percentage (≥3%) of virtual-hits 
identified by SVMs in screening 168K MDDR compounds for VEGFR-2 
inhibitors. The total number of SVM identified virtual hits is 2,717. 
 
MDDR Classes that Contain Higher 
Percentage (>3%) of Virtual Hits  
No and 
Percentage of 
Virtual Hits in 
Class  
Percentage of Class 
Members 
Selected as Virtual 
Hits 
Antineoplastic 1230 (45.3%) 5.7% 
Tyrosine-Specific Protein Kinase 
Inhibitor 
346 (12.7%) 29.3% 
Signal Transduction Inhibitor 345 (12.7%) 16.9% 
Antiarthritic 300 (11.0%) 2.6% 
Antiangiogenic 256 (9.3%) 15.7% 
Antihypertensive 139 (5.1%) 1.3% 
Antiallergic/Antiasthmatic 118 (4.3%) 1.1% 
Antidepressant 93 (3.4%) 1.5% 
 
5.2.3.3 Evaluation of SVM identified MDDR virtual-hits 
SVM identified MDDR virtual-hits were evaluated based on the known 
biological or therapeutic target classes specified in MDDR. Table 4 gives the 
MDDR classes that contain higher percentage (≥3%) of SVM virtual-hits and 
the percentage values. We found that 1,230 or 45.3% of the 2,717 virtual-hits 
belong to the antineoplastic class, which represent 5.7% of the 21,557 MDDR 
compounds in the class. In particular, 346 or 12.7% of the virtual-hits belong 
to the tyrosine-specific protein kinase inhibitor class, which represent 29.3% 
of the 1,181 MDDR compounds in the class. Moreover, 12.7% and 9.4% of 
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the virtual-hits belong to the signal transduction inhibitor and antiangiogenic 
classes, representing 16.9% and 15.7% of the 2,037 and 1,629 members in the 
two classes respectively. Therefore, many of the SVM virtual-hits are 
antineoplastic compounds that inhibit tyrosine kinases and possibly other 
kinases involved in signal transduction, angiogenesis and other cancer-related 
pathways. Some of these SVM selected kinase inhibitors might have VEGFR 
inhibitory activities, and others were expectedly selected due to false selection 
of inhibitors of other kinases (at ≤1.62%~12.36% false-hit rates).  
 
Substantial percentages of the SVM virtual-hits belong to the antiarthritic 
(11.0%), antihypertensive (5.1%), and antiallergic/antiasthmatic (4.3%) 
therapeutic classes. Some VEGFR inhibitors have been reported to show 
respective therapeutic effects. VEGF has been related to such autoimmune 
diseases as systemic lupus erythematosus, rheumatoid arthritis, and multiple 
sclerosis223. Both VEGFR-1 and VEGFR-2 are expressed in human 
osteoarthritic cartilage259. VEGFR-2 and VEGFR-3 are present in most of the 
sublining blood vessels in arthritic synovium260. A VEGFR-2 inhibitor, 
PTK787/ZK222584, has been reported to cause significant anti-arthritic 
effects in models of rheumatoid arthritis via anti-angiogenic actions124. 
Hypertension is characterized by the development of a hyperdynamic 
circulation which can be markedly inhibited by EGFR-2 inhibitor (e.g. 
SU5416) blockade of the VEGF signaling pathway, leading to the 
consideration of modulation of angiogenesis for the treatment of 
hypertension257. VEGFR-2 and VEGFR-1 have been shown to be involved in 
the pathogenesis of the contact hypersensitivity reaction, and both the 
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induction and elicitation phases of contact hypersensitivity can be inhibited by 
VEGFR inhibitor PTK787/ZK222584258. Therefore, some of the SVM virtual-
hits in the antiarthritic, antihypertensive, and antiallergic/antiasthmatic classes 
may be VEGFR inhibitors capable of producing the respective therapeutic 
effects.  
 
Moreover, 93 (3.4%) of the SVM virtual hits are in the antidepressant class. It 
has been reported that depressive episodes in the context of borderline 
personality disorder may be accompanied by increased serum concentrations 
of VEGF and FGF-2261. VEGF has been implicated in neuronal survival, 
neuroprotection, regeneration, growth, differentiation, and axonal outgrowth, 
which is involved in the pathophysiology of major depressive disorder and the 
higher expression levels of VEGF in the peripheral leukocytes are associated 
with the depressive state262. Therefore, there is a possibility that inhibition of 
VEGFR signalling may have some level of antidepressant effect or act as 
enhancer of other antidepressant agents263, and some of the SVM virtual hits 
in the antidepressant class may be possible VEGFR inhibitors that partly 
explain their antidepressant activities. 
 
5.2.3.4 Comparison of Virtual Screening Performance of SVM 
with Tanimoto-Based Similarity Searching Method 
To evaluate whether the performance of SVM is due to the SVM classification 
models or to the molecular descriptors used, SVM results were compared with 
those of the Tanimoto-based similarity searching method (please refer to 
Chapter 2 Section 2.3.4) based on the same molecular descriptors, training 
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dataset of VEGFR-2 inhibitors reported before 2008, and the testing dataset of 
VEGFR-2 inhibitors reported since 2008 and 168K MDDR compounds. The 
yield and false-hit rate of the Tanimoto-based similarity searching method is 
39.3% and 4.4% respectively. Compared to these results, the yield of SVM is 
significantly improved and the false-hit rate of SVM is substantially reduced. 
This suggests that SVM performance is due primarily to the SVM 
classification models rather than the molecular descriptors used. 
 
5.2.3.5 Does SVM select VEGFR inhibitors or membership of 
compound families? 
To further evaluate whether SVM identifies VEGFR-2 inhibitors rather than 
membership of certain compound families, Compound family distribution of 
the identified VEGFR-2 inhibitors and non-inhibitors were analyzed. A total 
of 53.5% of the identified VEGFR-2 inhibitors belong to the families that 
contain no known VEGFR-2 inhibitors. For those families that contain at least 
one known inhibitor, >70% of the compounds (>90% in majority cases) in 
each of these families were predicted as non-inhibitor by SVM. These results 
suggest that SVM identifies VEGFR-2 inhibitors rather than membership to 
certain compound families. Some of the identified inhibitors not in the family 
of known inhibitors may serve as potential “novel” VEGFR-2 inhibitors. 
Therefore, as in the case shown by earlier studies108, SVM has certain capacity 





5.2.4 Further perspective 
By using training dataset of more diverse spectrum of inactive compounds as 
well as substantial number of literature-reported VEGFR-2 inhibitors, SVM 
shows substantial capability in identifying VEGFR-2 inhibitors at comparable 
yield and in many cases substantially lower false-hit rate than those of typical 
VS tools reported in the literatures. It is capable of searching large compound 
libraries at sizes comparable to the 13.56M PubChem and 168K MDDR 
compounds at low false-hit rates without the need to define an applicability 
domain, i.e. it has a broad applicability domain that covers the whole chemical 
space defined by the PubChem and MDDR databases. The performance of 
SVM is significantly better than that of Tanimoto-based similarity search 
method based on the same datasets and molecular descriptors, suggesting that 
the VS performance of SVM is primarily due to SVM classification models 
rather than the molecular descriptors used. Because of their high computing 
speed and generalization capability for covering highly diverse spectrum 
compounds, SVM can be potentially explored to develop useful VS tools to 
complement other VS methods or to be used as part of integrated VS tools in 
facilitating the discovery of VEGFR inhibitors and other active 
compounds65,69,71. It is also possible to discover dual kinase inhibitor of c-Src 
and VEGFR based on our developed models in our further study. 
Chapter 6 Virtual Screening of Selective Multi‐Target Kinase Inhibitors 
  126 
Chapter 6 Virtual Screening of Selective Multi-Target 
Kinase Inhibitors 
Multi-target agents have been increasingly explored for enhancing efficacy 
and reducing counter-target activities and toxicities. Efficient virtual 
screening (VS) tools for searching selective multi-target agents are desired. In 
this chapter, combinatorial support vector machines (C-SVMs) were tested as 
VS tools for searching dual-inhibitors of 11 combinations of 9 anticancer 
kinase targets (EGFR, VEGFR, PDGFR, Src, FGFR, Lck, CDK1, CDK2, 
GSK3). This is another application of our high performance virtual screening 
tool in drug discovery. 
6.1 Introduction 
Large percentage of drugs in development, which are typically directed at an 
individual target, frequently show reduced efficacies and undesired safety and 
resistance profiles due to network robustness76, redundancy77, crosstalk78, 
compensatory and neutralizing actions79, anti-target and counter-target 
activities80, and on-target and off-target toxicities81. Multi-target agents and 
drug-combinations have been increasingly explored76,82 for enhancing 
therapeutic efficacies and improving safety and resistance profiles by 
selectively modulating the elements of these counter-target and toxicity 
activities83. In particular, multi-target kinase inhibitors are among the most 
successful clinical anticancer drugs (e.g. sunitinib against PDGFR and 
VEGFR, dasatinib against Abl and Src, sorafenib against Braf and VEGFR, 
and lapatinib against EGFR and HER2) and have been actively pursued in 
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current drug discovery efforts85,86. Methods for efficient search of multi-target 
agents are highly desired. 
 
Virtual screening (VS) methods have been widely explored for facilitating 
lead discovery against individual targets37,89,219.  In particular, molecular 
docking91, pharmacophore92, QSAR93, machine learning94, and combination 
methods95 have been extensively used for VS of single-target kinase 
inhibitors, but few multi-target VS studies have been reported264,265. An 
interesting strategy for identifying multi-target kinase inhibitors is to use  
experimentally obtained small-scale profiles for  predicting inhibitors of  a 
larger kinase set265. In principle, single-target VS tools may be combined to 
collectively identify multi-target agents, which is practically useful if the 
individual VS tools have sufficiently high yields and low false-hit rates. High 
yields compensate for the reduced collective yields of combinatorial VS tools 
(For two statistically-independent VS tools of 50%-70% yields, the collective 
yield of their combination is roughly the product of the yield of individual 
tools, which is 25%-49%). Low false-hit rates are needed for high enrichment 
factors in searching multi-target agents that are significantly fewer in numbers 
and more sparsely distributed in the chemical space than non-dual inhibitors 
(Table 6-1).  
 
An extensively-used machine learning method, support vector machines 
(SVM), may be potentially explored as multi-target VS tools because it has 
shown high yields and low false-hit rates in searching single-target agents108 
sometimes based on sparsely distributed active compounds219. SVM identifies 
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active compounds in fast-speed by differentiating physicochemical profiles 
rather than structural similarity to active compounds per se, and requires no 
knowledge of target structure and no computation of structural flexibility, 
activity-related features, solvation effects and binding affinities. Multi-target 
VS performance of combinatorial SVMs (C-SMV), which combine the 
prediction of two separate SVM classifier for each the multiple kinases, was 
tested by using them to search dual-inhibitors of combinations of 9 anticancer 
kinase targets EGFR, VEGFR, PDGFR, FGFR, Src, Lck, CDK1, CDK2, and 
GSK3. Figure 6-1 shows the illustration of using combinatorial support vector 
machines method (C-SVM) for searching multi-target inhibitors. These kinase 
targets were selected because of their therapeutic relevance and the availability 
of sufficient number of the known inhibitors and dual-inhibitors. The first six 
kinases belong to the protein kinase group PTK group and the last three 
belong to the CMGC group respectively.  
 
Figure 6-1 Illustration of using combinatorial support vector machines 





Based on dual-inhibitor availability, we focused on 11 kinase-pairs EGFR-
PDGFR, EGFR-FGFR, EGFR-Src, VEGFR-Lck, PDGFR-FGFR, PDGFR-
Src, Src-Lck, CDK1-CDK2, CDK1-GSK3, CDK2-GSK3, and CDK1-
VEGFR. The first 7 kinase-pairs are intra-PTK group, the 8th to 10th and intra-
CMGC group, and the 11th are inter-PTK-CMGC group kinase-pairs 
respectively, representative of different types of kinase-pairs.  These kinase-
pairs are frequently co-expressed or co-activated in various cancers266,267, and 
targeted by multi-target agents85,86 with good anticancer efficacies.  Inhibitors 
of growth factor receptor tyrosine kinases EGFR, VEGFR, PDGFR and FGFR 
have been successfully used for cancer treatments86,234,268-271. EGFR promotes 
proliferation and survival268. VEGFR regulates angiogenesis and survival234. 
PDGFR modulates angiogenesis and growth, and is one of the multi-targets of 
several approved and clinical trial drugs86,270. FGFR regulates angiogenesis 
and cancer progression, and is one of the multi-targets of several clinical trial 
drugs86,271. Src-family kinases Src and Lck modulate multiple pathways of cell 
growth, differentiation, migration and survival, and are part of the multi-
targets of several marketed and clinical trial drugs86,272. CDKs promote cell 
cycle progression, their inhibition severely limits the aberrant cell-cycle 
process in tumor and induces apoptosis, and CDK inhibitors are being 
developed and tested in clinical trials for anticancer therapeutics273. GSK3 
modulates glucose metabolism and the function of various proteins, and is 
associated with neurodegenerative diseases, stroke, bipolar disorder, diabetes 
and cancer274. GSK3 inhibitors have started to reach clinical development for 




Multi-target VS performance was tested by a rigorous method that assumes no 
explicit knowledge of known multi-target agents, because the number of 
known multi-target agents are generally small for many target-pairs. SVM of 
each kinase was trained by using non-dual inhibitors of that kinase. The 
collective yield of C-SVM of each kinase-pair (percent of known dual-
inhibitors identified as dual-inhibitors) was estimated by using known dual-
inhibitors of each kinase-pair. Target selectivity of each C-SVM was assessed 
by using non-dual inhibitors of the kinas-pair and inhibitors of the other 7 
kinases, out of the 9 evaluated kinases, not included in the kinase-pair. 
Virtual-hit rates and false-hit rates in searching large compound libraries were 
evaluated by using 13.56 million PubChem, 168 thousand compounds from 
the MDL Drug Data Report (MDDR) database, and 276-3,806 MDDR 
compounds similar in structural and physicochemical properties to the known 
dual-kinase inhibitors. MDDR contains biologically relevant compounds 
(active against individual molecular target or biological assay) and well-
defined derivatives reported in the patent literature, journals, meetings and 
congresses. PubChem and MDDR contain high percentages of inactive or 
active compounds significantly different from the dual-inhibitors, and the 
easily distinguishable features may make VS enrichments artificially good202. 
Therefore, VS performance is more strictly tested by using subset of MDDR 
compounds similar to the dual-inhibitors so that enrichment is not simply a 




VS performance of C-SVM was further compared with those of three VS 
methods, which include a popular molecular docking software DOCK version 
3.5.54 at the DOCK Blaster server275, a similarity-based statistical learning 
method k nearest neighbour (kNN) 73, and a machine-learning method 
probabilistic neural networks (PNN) 276  against the same sets of dual- and 
non-dual kinase inhibitors and 1.02 million Zinc clean-leads dataset (Zinc-
CLD) 111. The specific indicators to be compared are the dual-inhibitor yields 
for both intra-group and inter-group dual-kinase inhibitors, and the false-hit 
rates for non-dual kinase inhibitors and the Zinc-CLD dataset, which enable 
objective assessment of the capability of C-SVM with respect to those of the 
popular as well as machine learning based VS methods. 
6.2 Materials and methods 
6.2.1 Compound collection, training and testing datasets, 
molecular descriptors 
A total of 233-1,316 non-dual inhibitors of EGFR, VEGFR, PDGFR, FGFR, 
Src, Lck, CDK1, CDK2, and GSK3, and 41-230 dual inhibitors of EGFR-
PDGFR, EGFR-FGFR, EGFR-Src, VEGFR-Lck, PDGFR-FGFR, PDGFR-
Src, Src-Lck, CDK1-CDK2, CDK1-GSK3, CDK2-GSK3, and CDK1-
VEGFR, each with IC50≤10M, were collected from the literature277-286 and 
the BindingDB database110. Dual-inhibitors and non-dual inhibitors of a 
kinase-pair refer to inhibitors of both and one of the two kinases respectively 
regardless of their activities against other kinases. Table 6-1 summarises the 
statistics of these inhibitors and MDDR compounds similar to at least one 
dual-inhibitor. Figure 6-2 shows the Venn graph of our collected dual-
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inhibitors the 11 evaluated kinase pairs and non-dual-inhibitors of the 9 
evaluated kinases. As few non-inhibitors have been reported, putative non-
inhibitors of each kinase were generated by using our published method that 
requires no knowledge of inactive compounds or active compounds of other 
target classes and enables more expanded coverage of the “non-inhibitor” 
chemical space89,219. First, 13.56 million PubChem and 168 thousand MDDR 
compounds were clustered into 8,993 compound families of similar molecular 
descriptors189, which are consistent with the reported 12,800 compound-
occupying neurons (regions of topologically close structures) for 26.4 million 
compounds of up to 11 atoms3, and 2,851 clusters for 171,045 natural 
products190. A total of 42,670- 44,115 compounds extracted from the 8,534-
8,823 families (5 per family) that contain no known inhibitor were used as the 





Figure 6-2 The Venn graph of the collected dual-inhibitors the 11 evaluated 
kinase-pairs and non-dual-inhibitors of the 9 evaluated kinases. 
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Table 6-1 Datasets of dual-inhibitors and non-dual-inhibitors of the kinase-pairs used for developing and testing combinatorial 
SVM dual-inhibitor virtual screening tools.  Additional sets of 13.56 million PubChem compounds and 168 thousand MDDR 
active compounds were also used for the test. 
 
Kinase Pair  Inhibitors in Training Sets Inhibitors and Other Compounds in Testing Set 
Kinase A – 
Kinase B 
Training Set for Kinase A Training Set for Kinase B Dual Inhibitors of A and B Inhibitors 







A and B 
 No of 
inhibitors 
of A that 
are non-
inhibitor of 
B (No of 
families) 
No of  
these 
inhibitors 
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dual-
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inhibitor of 
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than 2 of 








EGFR-PDGFR 1316 (384) 336 (70) 100 (19) 622 (202) 251 (70) 153 (23) 58 (40) 22 (37.9%) 50 (86.2%) 3 (5.2%) 4097 3806 
EGFR-FGFR 1303 (388) 284 (52) 160 (22) 392 (131) 154 (52) 124 (27) 71 (39) 37 (52.1%) 70 (98.6%) 2 (2.8%) 4327 1001 
EGFR-Src 1262 (372) 331 (73) 166 (31) 748 (216) 243 (73) 168 (38) 112 (64) 46 (41.1%) 46 (41.1%) 2 (1.8%) 3971 1127 
VEGFR-Lck 1232 (427) 220 (69) 102 (17) 445 (171) 206 (69) 52 (11) 61 (23) 29 (47.5%) 37 (60.7%) 0 (0.0%) 4355 413
PDGFR-FGFR 450 (168) 100 (29) 118 (27) 233 (90) 89 (29) 79 (25) 230 (78) 90 (39.1%) 214 (93.0%) 3 (1.3%) 5180 3614 
PDGFR-Src 492 (174) 237 (53) 144 (24) 672 (213) 206 (53) 170 (38) 188 (67) 71 (37.8%) 184 (97.9%) 3 (1.6%) 4741 2893 
Src-Lck 804 (236) 222 (49) 98 (11) 450 (175) 160 (49) 23 (9) 56 (17) 23 (41.1%) 38 (67.9%) 0 (0.0%) 4783 276 
CDK1-CDK2 484 (199) 183 (52) 99 (28) 650 (251) 178 (52) 68 (34) 174 (84) 53 (30.5%) 24 (13.8%) 0 (0.0%) 4785 2629 
CDK1-GSK3 503 (224) 140 (45) 38 (20) 642 (266) 143 (45) 83 (22) 155 (51) 49 (31.6%) 17 (11.0%) 0 (0.0%) 4793 3279 
CDK2-GSK3 749 (280) 226 (62) 58 (23) 722 (275) 249 (62) 107 (24) 75 (44) 31 (41.3%) 17 (22.7%) 0 (0.0%) 4547 1617 
CDK1-VEGFR 651 (251) 250 (75) 23 (8) 1285(434) 251 (75) 70 (17) 41 (25) 7 (17.1%) 0 (0.0%) 0 (0.0%) 4149 427 
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The collected non-dual and dual inhibitors of EGFR, VEGFR, PDGFR, FGFR, 
Src, Lck, CDK1, CDK2, and GSK3 are distributed in 431, 456, 246, 170, 284, 
192, 255, 301, and 295 families respectively, which is consistent with reported 
191 unique scaffolds (154 clusters and 43 singletons) for 565 kinase 
inhibitors94.  Because of the extensive efforts in searching kinase inhibitors, 
the number of undiscovered “inhibitor” families for each kinase in PubChem 
and MDDR is expected to be relatively small, most likely no more than 
several hundred families. The ratio of the “inhibitor” and “inactive” families 
for each kinase (hundreds families vs 8,534-8,823 families contained in 
PubChem and MDDR at present) is expected to be no more than ~999/8500, 
which is <13%. Therefore, putative non-inhibitor training dataset can be 
generated by extracting a few representative compounds from each of the 
families that contain no known inhibitor, with a maximum possible “wrong” 
classification rate of <13% even in the extreme and unlikely cases that all of 
the undiscovered inhibitors are misplaced into the non-inhibitor class (please 
refer to Chapter 3 Section 3.2.2). The noise level generated by up to 13% 
“wrong” negative family represntation is expected to be substantially smaller 
than the maximum 50% false-negative noise level tolerated by SVM47. It is 
noted that 40%-62.2% of the dual-inhibitor families contain no non-dual 
inhibitor of the same kinase-pair, whose representative compounds were 
included in the inactive training datasets as dual-inhibitors are supposed to be 
unknown in our study. A substantial percentage of the dual-inhibitors in these 





A total of 98 important descriptors were chosen from the chemical descriptors 
calculated by our program MODEL which were used in this work. The detail 
about molecular descriptors is explained in Chapter 2 Section 2.2. 
6.2.2 Computational models 
SVM is based on the structural risk minimization principle of statistical 
learning theory145. It consistently shows outstanding classification 
performance, is less penalized by sample redundancy, has lower risk for over-
fitting, is capable of accommodating large and structurally diverse training and 
testing datasets, and is fast in performing classification tasks147,148. However, 
the performance of SVM is critically dependent on the diversity of training 
datasets. Because of the limited knowledge of known inhibitors for many 
kinase targets, sufficiently good SVM VS tools may not be readily developed 
for these targets. Non-the-less, SVM VS tools with comparable performances 
or partially improved performances in certain aspects (e.g. reduced false-hit 
rates at comparable inhibitor yield) are useful to complement other VS tools. 
The detailed mathematical algorithms of SVM are described in Chapter 2 
Section 2.3.1. Readers are referred to this section. Our SVM VS models were 
developed by using a hard margin c=100,000 and their  values are in the 
range of 0.1-2. In terms of the numbers of true positives TP (true inhibitors), 
true negatives TN (true non-inhibitors), false positives FP (false inhibitors), 
and false negatives FN (false non-inhibitors), the yield and false-hit rate are 
given by TP/(TP+FN) and FP/(TP+FP) respectively. 
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6.3 Results and discussion 
6.3.1 Dual-inhibitors and non-dual inhibitors of the studied 
kinase-pairs 
As shown in Table 6-1, the numbers of dual-inhibitors and non-dual inhibitors 
of the kinase-pairs are 58, 1,316 and 622 for EGFR-PDGFR, 71, 1,303 and 
392 for EGFR-FGFR, 112, 1,262 and 748 for EGFR-Src, 61, 1,232 and 445 
for VEGFR-Lck, 230, 450 and 233 for PDGFR-FGFR, 188, 492 and 672 for 
PDGFR-Src, 56, 804 and 450 for Src-Lck, 174, 484, and 650 for CDK1-
CDK2, 155, 503, and 642 for CDK1-GSK3, 75, 749, and 722 for CDK2-
GSK3, and 41, 651, and 1285 for CDK1-VEGFR respectively. The dual-
inhibitors and non-dual inhibitors are distributed in 17-84 and 90-427 families 
respectively. Hence, both the numbers and diversity of non-dual inhibitors and 
dual-inhibitors are at reasonable levels for developing and testing VS tools. 
The percentages of dual-inhibitors outside the common families of the non-
dual inhibitors in the training datasets are 62.1% for EGFR-PDGFR, 57.9% 
for EGFR-FGFR, 58.9% for EGFR-Src, 52.5% for VEGFR-Lck, 60.9% for 
PDGFR-FGFR, 62.2% for PDGFR-Src, 58.9% for Src-Lck, 69.5% for CDK1-
CDK2, 68.4% for CDK1-GSK3, 58.7% for CDK2-GSK3, and 82.9% for 
CDK1-VEGFR respectively. Therefore, these dual-inhibitors have substantial 
degree of novelty against non-dual inhibitors. Moreover, 0.0%-98.6% of the 
dual-inhibitors of the kinase-pairs are inhibitor of at least one of the other 7 
kinases, but only up to 5.2% of the dual-inhibitors are inhibitor of at least 3 of 
the other 7 kinases. Hence, most of these dual-inhibitors are non-ubiquitous 
inhibitors and show some degree of kinase selectivity even-though the 




Some distinguished features of dual-inhibitors may be probed by evaluating 
the top-6 scaffolds contained in higher percentages of the dual-inhibitors of 
the studied intra-PTK group kinase-pairs, which are shown in Figure 6-3. 
Table 6-2 shows the distribution of these scaffolds in the dual-inhibitors and 
non-dual-inhibitors of the studied intra-PTK group kinase-pairs. Scaffold A is 
contained in 63.8% of EGFR-PDGFR, 76.1% of PDGFR-Src, 33.9% of 
EGFR-Src, 54.9% of EGFR-FGFR and 27.8% of VEGFR-Lck dual-inhibitors 
respectively; Scaffold B is contained in 57.1% of Src-Lck, 29.5% of VEGFR-
Lck and 25.9% of EGFR-Src dual-inhibitors respectively. Scaffold A and 
scaffold B appear to be the backbone of majority of dual-inhibitors of the 
studied kinase-pairs. Scaffold C is mainly contained in 19.6% of EGFR-Src 
dual inhibitors. Scaffold D is mainly contained in 32.4% in EGFR-FGFR and 
4.5% in EGFR-Src dual-inhibitors. Scaffold E is contained in 17.8% of 
PDGFR-FGFR, 8.6% of EGFR-PDGFR, 7.0% of EGFR-FGFR and 6.9% of 
PDGFR-Src dual-inhibitors. Scaffold F is contained in 37.5% of Src-Lck and 
34.4% of VEGFR-Lck dual-inhibitors. These scaffolds are also contained, 
mostly at significantly lower percentage levels, in the non-dual inhibitors of at 
least one of the kinases of the respective kinase-pairs. Therefore, some 
specific variations of side-chain groups of these scaffolds appear to be 
sufficient to convert some dual-inhibitors into non-dual inhibitors, which 
suggest that physicochemical properties as well as structural features are 




























































Scaffold F  
 
Figure 6-3 Top-6 scaffolds contained in higher percentages of the dual-




Table 6-2 Distribution of top-6 scaffolds in dual-inhibitors of 7 intra-PTK group kinase combinations of EGFR, VEGFR, 
PDGFR, FGFR, Src and Lck, and non-dual inhibitors of the constituent kinases 
 

























EGFR-PDGFR Dual inhibitors 63.8% (37/58) 0% (0/58) 0% (0/58) 1.7% (1/58) 8.6% (5/58) 0% (0/58) 
EGFR non-dual 
inhibitors 
0.2% (3/1316) 6.3% (83/1316) 1.2% (16/1316) 7.7% (101/1316) 0% (0/1316) 0% (0/1316) 
PDGFR non-
dual inhibitors 
20.3% (126/622) 0% (0/622) 0% (0/622) 0% (0/622) 7.1% (44/622) 0% (0/622) 
EGFR-FGFR Dual inhibitors 54.9% (39/71) 0% (0/71) 0% (0/71) 32.4% (23/71) 7.0% (5/71) 0% (0/71) 
EGFR non-dual 
inhibitors 
0.1% (1/1303) 6.4% (83/1303) 1.2% (16/1303) 6.1% (79/1303) 0% (0/1303) 0% (0/1303) 
FGFR non-dual 
inhibitors 
25.5% (100/392) 0% (0/392) 0% (0/392) 2.3% (9/392) 10.0% (39/392) 0.3% (1/392) 
EGFR-Src Dual inhibitors 33.9% (38/112) 25.9% (29/112) 19.6% (22/112) 4.5% (5/112) 2.7% (3/112) 0% (0/112) 
EGFR non-dual 
inhibitors 
0.2% (2/1262) 4.3% (54/1262) 1.6% (20/1262) 7.7% (97/1262) 0.2% (2/1262) 0% (0/1262) 
Src non-dual 
inhibitors 
18.2% (136/748) 10.4% (78/748) 0.8% (6/748) 5.0% (37/748) 1.60% (12/748) 2.8% (21/748) 
VEGFR-Lck Dual inhibitors 27.9% (17/61) 29.5% (18/61) 0%  (0/61) 0%  (0/61) 0%  (0/61) 34.4% (21/61) 
VEGFR non-
dual inhibitors 
0.7% (8/1232) 0.8% (10/1232) 0% (0/1232) 5.4% (66/1232) 4.7% (58/1232) 0% (0/1232) 




PDGFR-FGFR Dual inhibitors 67.4% (155/230) 0% (0/230) 0% (0/230) 0% (0/230) 17.8% (41/230) 0% (0/230) 
PDGFR non-
dual inhibitors 
1.8% (8/450) 0% (0/450) 0% (0/450) 0.2% (1/450) 1.8% (8/450) 0% (0/450) 
FGFR non-dual 
inhibitors 
11.2% (26/233) 0% (0/233) 0% (0/233) 13.7% (32/233) 1.3% (3/233) 0.4% (1/233) 
PDGFR-Src Dual inhibitors 76.1% (143/188) 0% (0/188) 0% (0/188) 0% (0/188) 6.9% (13/188) 0% (0/188) 
PDGFR non-
dual inhibitors 
2.9% (14/492) 0% (0/492) 0% (0/492) 0.2% (1/492) 7.3% (36/492) 0% (0/492) 
Src non-dual 
inhibitors 
3.7% (25/672) 15.9% (107/672) 1.9% (13/672) 6.3% (42/672) 0.3% (2/672) 3.1% (21/672) 
Src-Lck Dual inhibitors 0% (0/56) 57.1% (32/56) 0% (0/56) 1.8% (1/56) 1.8% (1/56) 37.5% (21/56) 
Src non-dual 
inhibitors 
21.6% (174/804) 9.3% (75/804) 1.6% (13/804) 5.1% (41/804) 1.9% (15/804) 0% (0/804) 
Lck non-dual 
inhibitors 





6.3.2 Virtual screening performance of Combinatorial SVM in 
searching kinase dual-inhibitors from large libraries 
The VS performance of C-SVMs in identifying dual-inhibitors of the 11 
kinase-pairs is summarised in Table 6-3 and further shown in Figure 6-4.  
The parameters of the developed SVM classification models for the evaluated 
kinases are in the ranges of =0.5~0.8. The dual-inhibitor yields are 27.6% for 
EGFR-PDGFR, 40.9% for EGFR-FGFR, 26.8% for EGFR-Src, 52.6% for 
VEGFR-Lck, 33.9% for PDGFR-FGFR, 38.3% for PDGFR-Src, 48.2% for 
Src-Lck, 52.3% for CDK1-CDK2, 49.0% for CDK1-GSK3, 57.3% for CDK2-
GSK3, and 12.2% for CDK1-VEGFR respectively. The yields for the intra-
PTK group and intra-CMGC group kinase pairs are comparable to the 
expected 25%-49% yields of combinations of good VS tools with individual 
yields of 50%-70%. Therefore, C-SVMs show reasonably good capability in 
identifying multi-target agents for kinase-pairs within a protein kinase group 
without requiring explicit knowledge of multi-target agents. However, the 
yield for the inter-PTK-CMGC kinase group CDK1-VEGFR kinase-pair is 
only 12.2%, which is significantly lower than those for the intra-PTK group 
and intra-CMGC group kinase-pairs. Structural analysis of the inhibitors of 
CDK1 and VEGFR binding sites has revealed that inhibitors generally make 
extensive favorable van der Waals contacts and several hydrogen bonds with 
Lys33, Leu83 and Asp86 at the hinge region of CDK1, and with Cys919, 
Asn923, Cys1045 and Asp1046 at the hinge region of VEGFR respectively, 
relatively small structural changes may easily reduce the optimal fit to the 
binding site, and some dual-inhibitors are able to bind to both kinases because 
of their structural flexibility to tolerate the different binding site geometry and 
Chapter 6 Virtual Screening of Selective Multi‐Target Kinase Inhibitors 
  143 
to form alternative hydrogen bonds287. In some cases, dual selectivity of 
inhibitors of inter-kinase-group kinase-pairs may require structural flexibility 
to fit in a hydrophobic pocket conserved in both kinase classes288. Such special 
structural features in dual-inhibitors of inter-kinase-group kinase-pairs are not 
necessarily needed and thus may not be found in non-dual inhibitors of 
individual kinases used in our training datasets, which likely be an important 
reason for the reduced yield of C-SVM in identifying CDK1-VEGFR dual-
inhibitors. The smaller number of known CDK1-VEGFR dual-inhibitors may 
also affect the accurate assessment of VS outcome. 
 
Figure 6-4 The VS performance of C-SVMs in identifying dual-inhibitors of 




Table 6-3 Virtual screening performance of combinatorial SVMs for identifying dual-inhibitors of 11 combinations of EGFR, 
VEGFR, PDGFR, FGFR, Src, Lck, CDK1, CDK2, and GSK3 
 
Kinase  Virtual Screening Performance 
  Dual inhibitors Non-dual inhibitors of 






































False hit rate  Virtual hit 
rate (No of 
virtual hits) 
Virtual hit 
rate (No of 
virtual hits) 
Virtual hit rate 
(No of virtual 
hits) 
Virtual hit rate 
(No of virtual 
hits) 
EGFR-PDGFR 27.60% 9 (15.5%) 9.20% 14.30% 1.88% 1.5% (57) 0.10% (175) 0.031% (4155) 0.025% (257) 
EGFR-FGFR 40.90% 6 (8.5%) 10.10% 8.70% 1.06% 6.5% (65) 0.07% (126) 0.016% (2200) 0.004% (36) 
EGFR-Src 26.80% 13 (11.6%) 12.90% 11.10% 1.49% 2.13% (24) 0.096% (162) 0.033% (4471) 0.007% (76) 
VEGFR-Lck 52.60% 8 (13.1%) 6.60% 29.20% 2.80% 5.1% (21) 0.10% (170) 0.036% (4817) 0.011% (113) 
PDGFR-FGFR 33.90% 35 (15.2%) 15.60% 22.30% 0.98% 1.4% (51) 0.057% (95) 0.013% (1746) 0.0008% (8) 
PDGFR-Src 38.30% 30 (16.0%) 25.80% 11.60% 1.81% 2.9% (84) 0.104% (175) 0.021% (2799) 0.001% (14) 
Src-Lck 48.20% 9 (16.1%) 15.80% 18.70% 0.98% 9.4% (26) 0.078% (131) 0.020% (2674) 0.002% (25) 
CDK1-CDK2 52.30% 57 (32.8%) 39.20% 48.10% 3.39% 0.34% (9) 0.075% (126) 0.022% (2953) 0.014% (139) 
CDK1-GSK3 49.00% 41 (26.5%) 38.40% 37.40% 4.30% 0.30% (10) 0.028% (47) 0.016% (2218) 0.016% (159) 
CDK2-GSK3 57.30% 24 (32.0%) 36.80% 37.70% 2.99% 0.43% (7) 0.085% (142) 0.021% (2901) 0.020% (203) 
CDK1-VEGFR 12.20% 0 (0.0%) 14.00% 3.70% 4.77% 0.0% (0) 0.007% (12) 0.023% (3113) 0.002% (19) 
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Target selectivity was tested by using C-SVMs to screen the 233-1,316 non-
dual inhibitors of the 11 kinase-pairs, which misidentified 9.2% and 14.3% of 
the non-dual inhibitors of the kinase-pair as dual-inhibitors for EGFR-PDGFR, 
10.1% and 8.7% for EGFR-FGFR, 12.9% and 11.1% for EGFR-Src, 6.6% and 
29.2% for VEGFR-Lck, 15.6% and 22.3% for PDGFR-FGFR, 25.8% and 
11.6% for PDGFR-Src, 15.8% and 18.7% for Src-Lck, 39.2% and 48.1% for 
CDK1-CDK2, 38.4% and 37.4% for CDK1-GSK3, 36.8% and 37.7% for 
CDK2-GSK3, and 14.0% and 3.7% for CDK1-VEGFR respectively. 
Therefore, C-SVMs are reasonably selective in distinguishing dual-inhibitors 
from non-dual inhibitors. There are two possible reasons for the 
misidentification of a substantial percentage of non-dual inhibitors as dual-
inhibitors. First, SVMs were trained by non-dual inhibitors only, which may 
not fully distinguish dual and non-dual inhibitors. Secondly, some of the 
misidentified non-dual inhibitors are probably true dual-inhibitors not yet 
experimentally tested for multi-target activities. It is noted that “mistaken” 
selection of these non-dual inhibitors is still useful for searching single-target 
leads. 
 
Target selectivity was further tested by using C-SVMs to screen the 3,971-
5,180 inhibitors of the other 7 kinases not included in a particular kinase-pair. 
We found that 1.88% of these inhibitors were misidentified as dual-inhibitors 
for EGFR-PDGFR, 1.06% for EGFR-FGFR, 1.49% for EGFR-Src, 2.80% for 
VEGFR-Lck, 0.98% for PDGFR-FGFR, 1.81% for PDGFR-Src, 0.98% for 
Src-Lck, 3.39% for CDK1-CDK2, 4.30% for CDK1-GSK3, 2.99% for CDK2-
GSK3, and 4.77% for CDK1-VEGFR respectively. These showed that C-
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SVMs are fairly selective in separating inhibitors of specific kinase-pair from 
those of other kinases.  
 
Virtual-hit rates and false-hit rates of C-SVMs in screening compounds that 
resemble the structural and physicochemical properties of the training datasets 
were evaluated by using 276-3,614 MDDR compounds similar to a dual-
inhibitor of each kinase-pair. Similarity was defined by Tanimoto similarity 
coefficient ≥0.9 between a MDDR compound and its closest dual-inhibitor219. 
C-SVMs identified 57 virtual-hits from 3,806 MDDR similarity compounds 
(virtual-hit rate 1,5%) for EGFR-PDGFR, 65 from 1,001 MDDR compounds 
(6.5%) for EGFR-FGFR, 24 from 1,127 MDDR compounds (2.1%) for 
EGFR-Src, 21 from 413 MDDR compounds (5.1%) for VEGFR-Lck, 51 from 
3,614 MDDR compounds (1.4%) for PDGFR-FGFR, 84 from 2,893 MDDR 
compounds (2.9%) for PDGFR-Src, 26 from 276 MDDR compounds (9.4%) 
for Src-Lck, 9 from 2,629 MDDR compounds (0.34%) for CDK1-CDK2, 10 
from 3,279 MDDR compounds (0.30%) for CDK1-GSK3, 7 from 1,617 
MDDR compounds (0.43%) for CDK2-GSK3, and 0 from 505 MDDR 
compounds (0.0%) for CDK1-VEGFR respectively.  
 
Significantly lower virtual-hit rates and thus false-hit rates were found in 
screening large libraries of 168 thousand MDDR and 13.56 million PubChem 
compounds.  The numbers of virtual-hits and virtual-hit rates in screening 168 
thousand MDDR compounds are 175 and 0.1% for EGFR-PDGFR, 126 and 
0.07% for EGFR-FGFR, 162 and 0.096% for EGFR-Src, 170 and 0.1% for 
VEGFR-Lck, 95 and 0.057% for PDGFR-FGFR, 175 and 0.104% for 
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PDGFR-Src, and 131 and 0.078% for Src-Lck, 126 and 0.075% for CDK1-
CDK2, 47 and 0.028% for CDK1-GSK3, 142 and 0.085% for CDK2-GSK3 
and 12 and 0.007% for CDK1-VEGFR respectively. The numbers of virtual-
hits and virtual-hit rates in screening 13.56M PubChem compounds are 4,155 
and 0.031% for EGFR-PDGFR, 2,200 and 0.015% for EGFR-FGFR, 4,471 
and 0.033% for EGFR-Src, 4,817 and 0.036% for VEGFR-Lck, 1,746 and 
0.013% for PDGFR-FGFR, 2,799 and 0.021% for PDGFR-Src, 2,674 and 
0.02% for Src-Lck, 2,953 and 0.022% for CDK1-CDK2, 2,218 and 0.016% 
for CDK1-GSK3, 2,901 and 0.021% for CDK2-GSK3, and 3,113 and 0.023% 
for CDK1-VEGFR respectively.  
 
Substantial percentages of the MDDR virtual-hits belong to the classes of 
antineoplastic, tyrosine-specific protein kinase inhibitors, and signal 
transduction inhibitors (Table 6-5, details in next section). As some of these 
virtual-hits may be true dual-inhibitors, the actual number of true false-hits 
may be smaller than the total number of virtual-hits for each kinase-pair. 
Hence, the false-hit rates of our combinatorial SVMs are at most equal to and 
likely less than the virtual-hit rates. Hence the false-hit rates are ≤1.4%-9.4% 
in screening 276-3,614 MDDR similarity compounds, ≤0.057%-0.104% in 
screening 168 thousand MDDR compounds, and ≤0.013%-0.036% in 
screening 13.56 million PubChem compounds, which are comparable and in 
some cases better than single-target false-hit rates of 0.0054%-8.3% of single-
target SVMs89,219, 0.08%-3% of structure-based methods, 0.1%-5% by other 
machine learning methods, 0.16%-8.2% by clustering methods, and 1.15%-




6.3.3 Comparison of the performance of Combinatorial SVM 
with other virtual screening methods  
The VS performance of C-SVMs was further compared with DOCK 3.5.54 at 
the DOCK Blaster server275, kNN73, and PNN276 by using the common testing 
datasets composed of 41~230 dual-inhibitors of the 11 evaluated kinase-pairs 
(set-1), 3,971~5,180 non-dual inhibitors of the 9 evaluated kinases (set-2), and 
1.02 million Zinc clean-leads dataset (Zinc-CLD) 111 (set-3)  respectively. 
DOCK VS studies were conducted against the protein crystal structures 
typically used in DOCK Blaster VS studies275. Specifically, the PDB entry for 
EGFR, FGFR, c-Src, VEGFR, CDK2, Lck, and GSK3 are 3BEL, 3C4F, 
1YOL, 1Y6B, 2A4L, 2OG8, and 1Q5K respectively275.  Moreover, a modelled 
3D structure of PDGFR in the well-established molecular docking 
benchmarking sets158  was used for PDGFR. CDK1 was not evaluated because 
we were unable to find a published experimental or modelled 3D structure.  
 
In DOCK studies, the dual-inhibitor yield was estimated based on the 
screening results of set-1 and set-2 compounds, which is the percentage of the 
known dual-inhibitors made to the top-50% of the successfully docked set-1 
and set-2 compounds for every kinase of a kinase-pair, the false-hit rate for 
misidentifying inhibitors of other 7 kinases as dual-inhibitors of a kinase-pair 
is the percentage of these inhibitors made to the top-50% of the successfully 
docked set-1 and set-2 compounds for every kinase of that kinase-pair, and the 
virtual-hit rate for the Zinc-CLD compounds is the percentage of these 
compounds made to the top-2% of the successfully docked set-3 compounds 
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for every kinase of that kinase-pair. The kNN and PNN methods and software 
used in this study were described in Chapter 2 Section 2.3.2 and Section 
2.3.3. The training datasets of kNN and PNN and the methods for estimating 
the yield and virtual hit rate are the same as those of SVM. The parameters of 
the developed k-NN and PNN classification models for the evaluated kinases 
are in the ranges of k=1 or 3, and δ=0.003~0.11 respectively. The CPU time is 
~0.12, ~8, and ~5.5 hours per kinase target of SVM, kNN, and PNN models in 
screening the 1.02 million Zinc clean-leads dataset respectively. The 
classification speed of SVM is faster than that of k-NN and PNN due to the 
fact that SVM typically uses 0.007~0.017% of the training dataset as support 
vectors for classification, whereas k-NN and PNN use the whole training 
dataset. It took ~ 2 weeks to get the docking results from the DOCK Blaster 
server for screening the whole Zinc clean-leads dataset per kinase target. 
 
Table 6-4 and Figure 6-5 shows the comparison of the performance of C-
SVMs with the other three VS methods for identifying dual-inhibitors of 11 
combinations of EGFR, VEGFR, PDGFR, FGFR, Src, Lck, CDK1, CDK2, 
and GSK3 from the three common testing datasets. Overall, the yields of all 
VS methods are comparable, mostly in the ranges of 21.3%~57.3% for the 
intra-PTK and intra-CMGC group kinase-pairs and 12.2%~19.5% for the 
inter-PTK-CMGC group kinase-pair. C-SVM, kNN and PNN also produced 
comparable false hit-rates, at 0.98%~6.05%, for misidentifying inhibitors of 
other 7 kinases as dual-inhibitors of the evaluated kinase-pairs, with SVM 





For the 8 kinase-pairs with available 3D structure, DOCK produced higher 
false hit-rates than other three evaluated VS methods in misidentifying 
inhibitors of other 7 kinases as dual-inhibitors. These false-hit rates may be 
significantly reduced by adjusting the docking cut-off values for individual 
kinases, e.g. from top-50% to top-10%, which may however lead to 
significantly reduced yields.  High false-positive rates has been a common 
issue in structure-based VS, and the false-positives in kinase docking studies 
arise partly from the inability to favourably score certain key hydrogen-
binding interactions required for kinase binding and to discriminate 
conformational artifacts of docked ligands60. False-hit rates can be 
significantly reduced by such strategies as the incorporation of the reported 
kinase binding features into docking constrains60, consensus scoring using 
multiple ligand information and maximum common binding modes for 
multiple kinases105, and combining docking with pharmacophore filtering289. 
 
C-SVM produced substantially lower virtual-hit rates (0.008%~0.025%) than 
those (0.009%~0.348%) of the other three VS methods for identifying the 
Zinc-CLD compounds as virtual dual-inhibitors of the evaluated kinase-pairs. 
The numbers of Zinc-CLD compounds identified as virtual-hits by C-SVM are 
in the range of 8~203, compared to those of 1439~3963, 96~1406, and 
332~2830 by DOCK, kNN, and PNN respectively. The numbers of un-
discovered dual-inhibitors of the evaluated kinase-pairs in the Zinc-CLD are 
un-known. It is noted that only 12.1% of the known dual-inhibitors of the 
evaluated kinase-pairs and 14.0% the known non-dual inhibitors of the 
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evaluated kinases satisfy the criteria used for assembling the Zinc-CLD. 
Therefore, the numbers of un-discovered dual-inhibitors in the Zinc-CLD are 
expected to be very small, most likely fewer than 100. Based on this estimate, 
the minimum and maximum numbers of false-hits of C-SVM, DOCK, kNN, 
and PNN are 0~103 and 8~203, 1339~3863 and 1439~3963, 0~1306 and 
96~1406, and 232~2730 and 332~2839 respectively. C-SVM appears to show 
substantially lower false-hit rates than those of the other three VS methods in 
screening a large compound database. 
 
 
Figure 6-5 The comparison of the performance of C-SVMs with the other 
three VS methods DOCK, kNN and PNN for identifying dual-inhibitors of 11 
combinations of EGFR, VEGFR, PDGFR, FGFR, Src, Lck, CDK1, CDK2, 
and GSK3. The labels S, D, K, P beneath the performance bars represent C-
SVM, DOCK, kNN, and PNN respectively.
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Table 6-4 Comparison of the performance of combinatorial SVMs with other virtual screening methods for identifying dual-
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27.60% 1.88% 0.025% 
(257) 
34.50% 2.88% 0.112% 
(1144) 
36.20% 3.49% 0.217% 
(2211) 




40.90% 1.06% 0.004% 
(36) 
52.50% 2.22% 0.057% 
(579) 
56.30% 3.03% 0.095% 
(971) 




26.80% 1.49% 0.007% 
(76) 
29.50% 2.90% 0.081% 
(824) 
37.50% 4.53% 0.107% 
(1095) 




52.60% 2.80% 0.011% 
(113) 
42.60% 3.33% 0.091% 
(927) 
49.20% 4.55% 0.167% 
(1700) 






33.90% 0.98% 0.0008% 
(8) 
31.30% 2.51% 0.009% 
(96) 
46.50% 4.27% 0.033% 
(332) 




38.30% 1.81% 0.001% 
(14) 
40.40% 3.27% 0.048% 
(494) 
48.40% 4.41% 0.105% 
(1070) 
14.40% 19.45% 0.144% 
(1468) 
Src-Lck 48.20% 0.98% 0.002% 
(25) 
50.00% 2.26% 0.029% 
(294) 
53.60% 2.82% 0.037% 
(376) 




52.30% 3.39% 0.014% 
(139) 
18.40% 2.03% 0.135% 
(1377) 
21.30% 2.97% 0.367% 
(3738) 
N.A N.A N.A 
CDK1-
GSK3 
49.00% 4.30% 0.016% 
(159) 
32.30% 2.51% 0.131% 
(1331) 
37.40% 4.27% 0.281% 
(2865) 
N.A N.A N.A 
CDK2-
GSK3 
57.30% 2.99% 0.020% 
(203) 
32.00% 2.31% 0.118% 
(1203) 
41.30% 2.88% 0.245% 
(2498) 




12.20% 4.77% 0.002% 
(19) 
17.10% 5.01% 0.138% 
(1409) 
19.50% 6.05% 0.278% 
(2830) 
N.A N.A N.A 
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6.3.4 Evaluation of Combinatorial SVM identified MDDR 
virtual-hits 
C-SVM identified MDDR virtual-hits were evaluated based on the known 
biological or therapeutic target classes specified in MDDR. Table 6-5 gives 
the MDDR classes that contain higher percentage (≥9%) of C-SVM virtual-
hits and the percentage values. We found that 58-110 or 50%-62% of the 95-
175 virtual-hits belong to the antineoplastic class, which represent 0.30%-
0.51% of the 21,557 MDDR compounds in the class. In particular, 34-71 or 
21%-40% of the virtual-hits belong to the tyrosine-specific protein kinase 
inhibitor class, which represent 2.9%-6.0% of the 1,181 MDDR compounds in 
the class. Moreover, 13%-28% and 9%-14% of the virtual-hits belong to the 
signal transduction inhibitor and antiangiogenic classes, representing 0.83%-
2.4% and 0.98%-1.5% of the 2,037 and 1,629 members in the two classes 
respectively. Therefore, many of the C-SVM virtual-hits are antineoplastic 
compounds that inhibit tyrosine kinases and possibly other kinases involved in 
signal transduction, angiogenesis and other cancer-related pathways. While 
some of these kinase inhibitors might be true dual-inhibitors of specific 
kinase-pairs, the majority of them are expected to arise from false selection of 
non-dual inhibitors of the same kinase-pairs (at 6.6%-29.2% false-hit rates) 
and inhibitors of other kinases (at 0.2%-12.7% false-hit rates).  
 
Some of the C-SVM virtual-hits belong to the antiarthritic class. Five of our 
evaluated kinases or their kinase-likes have been linked to arthritis in the 
literature. EGFR-like receptor stimulates synovial cells and its elevated 
activities may be involved in the pathogenesis of rheumatoid arthritis89. VEGF 
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has been related to such autoimmune diseases as systemic lupus 
erythematosus, rheumatoid arthritis, and multiple sclerosis223. FGFR may 
partly mediates osteoarthritis224. PDGF-like factors stimulates the proliferative 
and invasive phenotype of rheumatoid arthritis synovial connective tissue 
cells225. Lck inhibition leads to immunosuppression and has been explored for 
the treatment of rheumatoid arthritis and asthma226. Therefore, some of the C-
SVM virtual-hits in the antiarthritic class may be inhibitors of our evaluated 
kinases or their kinase-likes capable of producing antiarthritic activities.  
 
Moreover, some of the C-SVM virtual-hits for PDGFR-FGFR belong to the 
atherosclerosis therapy class. Both kinases have been implicated in 
atherosclerosis. PDGF drives pathological mesenchymal responses in such 
vascular disorders as atherosclerosis, restenosis, pulmonary hypertension, 
retinal diseases, and fibrotic diseases290. Multiple FGFRs are elevated in 
therosclerotic lesions in apoE-/- micand and active FGFR-1 signalling 
promotes atherosclerosis development via increased SMC proliferation and by 
augmenting macrophage accumulation via increased expression of MCP-1 and 
factors promoting macrophage retention in lesions291. Therefore, some of the 






Table 6-5  MDDR classes that contain higher percentage (≥9%) of virtual-hits identified by combinatorial SVMs in screening 
168 thousand MDDR compounds for dual-inhibitors of 11 combinations of EGFR, VEGFR, PDGFR, FGFR, Src, Lck, CDK1, 
CDK2, and GSK3. 
 
Kinase Pair No of SVM 
Identified Virtual 
Hits 
MDDR Classes that Contain Higher Percentage of Virtual Hits No of Virtual 
Hits in Class 
Percentage of Class 
member as Virtual 
Hits 
EGFR-PDGFR 175 Antineoplastic 110 0.50% 
Tyrosine-Specific Protein Kinase Inhibitor 71 6.00% 
Signal Transduction Inhibitor 39 2.00% 
Antiangiogenic 25 1.50% 
Antiarthritic 21 0.20% 
EGFR-FGFR 126 Antineoplastic 78 0.40% 
Tyrosine-Specific Protein Kinase Inhibitor 47 4.00% 
Antiarthritic 37 0.30% 
Signal Transduction Inhibitor 23 1.10% 
Antiangiogenic 16 1.00% 
EGFR-Src 162 Antineoplastic 95 0.40% 
Tyrosine-Specific Protein Kinase Inhibitor 42 3.60% 
Signal Transduction Inhibitor 39 1.90% 
Antiangiogenic 21 1.30% 
Antiarthritic 15 0.10% 
VEGFR-Lck 170 Antineoplastic 87 0.40% 
Antiarthritic 42 0.40% 
Tyrosine-Specific Protein Kinase Inhibitor 36 3.00% 
Signal Transduction Inhibitor 31 1.50% 
Antiangiogenic 16 1.00% 
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PDGFR-FGFR 95 Antineoplastic 58 0.30% 
Tyrosine-Specific Protein Kinase Inhibitor 27 2.30% 
Signal Transduction Inhibitor 22 1.10% 
Atherosclerosis Therapy 10 0.90% 
Antiarthritic 10 0.10% 
PDGFR-Src 175 Antineoplastic 103 0.50% 
Signal Transduction Inhibitor 49 2.40% 
Tyrosine-Specific Protein Kinase Inhibitor 40 3.40% 
Antiangiogenic 16 1.00% 
Src-Lck 131 Antineoplastic 65 0.30% 
Tyrosine-Specific Protein Kinase Inhibitor 34 2.90% 
Antiarthritic 23 0.20% 
Signal Transduction Inhibitor 17 0.80% 
Antineoplastic Enhancer 14 2.20% 
CDK1-CDK2 126 Antineoplastic 87 0.40% 
Protein Kinase C Inhibitor 23 4.02% 
Antiviral 20 0.51% 
Tyrosine-Specific Protein Kinase Inhibitor 19 1.61% 
Signal Transduction Inhibitor 14 0.69% 
CDK1-GSK3 47 Antineoplastic 27 0.13% 
Tyrosine-Specific Protein Kinase Inhibitor 10 0.85% 
Antihypertensive 5 0.05% 
Protein Kinase C Inhibitor 5 0.87% 
Antidepressant 4 0.06% 
CDK2-GSK3 142 Antineoplastic 100 0.46% 
Protein Kinase C Inhibitor 28 4.90% 
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Antihypertensive 21 0.19% 
Antiviral 20 0.51% 
Signal Transduction Inhibitor 18 0.88% 
CDK1-VEGFR 12 Antineoplastic 5 0.02% 
Tyrosine-Specific Protein Kinase Inhibitor 3 0.25% 
Neuronal Injury Inhibitor 2 0.04% 
Antiangiogenic 2 0.12% 




6.3.5 Does Combinatorial SVM select kinase inhibitors or 
membership of compound families? 
To further evaluate whether C-SVMs identify kinase inhibitors rather than 
membership of certain compound families, Compound family distribution of 
the identified dual-inhibitors of the 7 intra-PTK group kinase-pairs were 
analyzed. As shown in Table 6-4, 15.5%, 8.5%, 11.6%, 13.1%, 15.2%, 16.0% 
and 16.1% of the identified EGFR-PDGFR, EGFR-FGFR, EGFR-Src, 
VEGFR-Lck, PDGFR-FGFR, PDGFR-Src, and Src-Lck dual-inhibitors are 
outside the families that contain at least one pair of non-dual inhibitors of the 
two kinases of the kinase-pair (i.e., at least one inhibitor for kinase A and one 
inhibitor for kinase B). For those families that contain at least one pair of non-
dual inhibitors of the two kinases of a kinase-pair, 17.2%-68.2% of the 
compounds (>40.0% in majority cases) in each of these families were 
predicted as non-dual inhibitors by C-SVMs. These results suggest that C-
SVMs identify dual-inhibitors not solely based on membership to certain 
compound families. 
 
6.3.6 Molecular features important for selecting dual-kinase 
inhibitors 
The molecular features important for selecting dual-kinase inhibitors were 
preliminarily analyzed by testing the VS performance with varying sets of 
molecular descriptors. Our analysis suggested that the VS performance is 
critically dependent on a proper combination of multiple simple molecular 
property descriptors that reflect ring and hydrogen binding features, chemical 
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property descriptors that represent hydrophobicity and molecular 
polarizability, molecular connectivity and shape profile descriptors that define 
the structural and flexibility features, and electro-topological state descriptors 
that determine the molecular skeletons, structural frameworks and their 
electronic properties. Our analysis is consistent with the reported structural 
analysis of the inhibitors of CDK1 and VEGFR that shows the importance of 
molecular structures for making extensive van der Waals contacts, hydrogen 
bonding with specific residues in both kinases, and structural flexibility to 
accommodate the different binding site geometry and to allow the formation 
of alternative hydrogen bonds. Our analysis is also consistent with another 
report that dual-kinase binding may require a combination of structural 
flexibility and the favourable hydrophobic interactions at specific pocket 
conserved in both kinase classes. Moreover, many dual-inhibitors adopt 
specific scaffolds, such as those illustrated in Figure 6-3, that enable them to 
more easily fit to the particular regions of the ATP site, which may be partly 
captured by the electro-topological state descriptors. A more comprehensive 
analysis using structural-based and feature selection methods may shed more 
light on the detailed molecular features of dual-kinase inhibition as well as 
single kinase inhibition. 
6.4 Further perspective 
Combinatorial SVM VS tools developed by using non-dual inhibitors show 
good capability in identifying dual-inhibitors of several anticancer target 
kinase-pairs at comparable and in many cases substantially lower false-hit 
rates than those of typical VS tools reported in the literatures. The capability 
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of the combinatorial SVMs and other VS tools in identifying multi-kinase 
inhibitors and other multi-target agents may be further enhanced by 
incorporating knowledge of multi-target agents into VS tool development 
processes. With the discovery of increasing number of selective multi-target 
agents from the current and future drug discovery efforts, it is possible to 
introduce more comprehensive elements of distinguished structural and 
physicochemical features of selective multi-target agents into the training of 
combinatorial VS tools for more effective identification of selective multi-
target agents. These multi-target VS tools may be combined with structure-
based filters for enhanced target selectivity. Because of their high computing 
speed and generalization capability, combinatorial SVM can be potentially 
explored to develop useful VS tools to complement other VS methods or to be 
used as part of integrated VS tools in facilitating the discovery of multi-kinase 
inhibitors and other multi-target agents. 
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Chapter 7 Concluding Remarks 
This last chapter summarizes the major findings and contributions of this 
study (Section 7.1). Limitation of present study and suggestion on possible 
areas for further studies are discussed in Section 7.2. 
7.1 Major findings and contributions 
Machine learning methods have been explored for developing such alternative 
VS tools because of their high-CPU speed and capability for covering highly 
diverse spectrum of compounds. However, while exhibiting equally good hit 
selection performance in screening extremely-large and large libraries, the 
currently developed machine learning tools tend to show lower hit-rate and, in 
some cases, lower enrichment factor than the best performing SBVS tools. 
This work selected the most popular ML method support vector machine to 
test whether the performance of SVM can be improved by using training-sets 
of diverse inactive compounds. Apart from the use of known inactive 
compounds and active compounds of other biological target classes as putative 
inactive compounds. This approach was applied for generating putative 
inactive compounds. An advantage of this approach is its independence on the 
knowledge of known inactive compounds and active compounds of other 
biological target classes, which enables more expanded coverage of the 
“inactive” chemical space in cases of limited knowledge of inactive 
compounds and compounds of other biological classes. In retrospective 
database screening of active compounds from large libraries such as 
PubChem, MDDR and ZINC, The hit-rates of our methods are comparable 
and the enrichment factors are substantially better than the best results of other 
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VS tools. The putative negatives generation method plays an important role in 
it. This method greatly increased the performance of VS without losing much 
positive accuracy. It showed that at the study of chemistry and biological 
problems, certain assumption could be made to solve the problems although 
sometimes it may lead to certain degree of noise. 
 
This work also evaluated the performance of SVM trained by sparsely 
distributed actives (regularly sparse and very sparse actives) in six MDDR 
biological target classes composed of high number of known actives 
(983~1,645) of high, intermediate, and low structural diversity (muscarinic 
M1 receptor agonists, NMDA receptor antagonists, thrombin inhibitors, HIV 
protease inhibitors, cephalosporins, and rennin inhibitors). Comparing the 
results with those of data fusion method, the yields of our regularly sparse 
SVM models are slightly improved for the high and intermediate classes, and 
the false-hit rates of our SVM models are substantially reduced for all three 
classes. These results suggest that, by using the equally small number of active 
compounds as training data, SVM is capable of producing equally good or 
slightly better yields and generalization capability at substantially reduced 
false-hit rates than those of the data fusion method. It was also found that our 
SVM models have substantial capability in identifying novel active 
compounds from sparse active datasets at low false-hit rates. An important 
feature of these SVM virtual screening methods is that they have 
generalization capability for covering highly diverse spectrum compounds. 
Even based on the sparse active datasets, SVM also can be potentially used to 
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develop useful VS (virtual screening) tools or be used as part of integrated VS 
tools in facilitating lead discovery. 
 
By using training dataset of more diverse spectrum of inactive compounds as 
well as substantial number of literature-reported c-Src and VEGFR-2 
inhibitors, the results of SVM based virtual screening shows substantial 
capability in identifying c-Src and VEGFR-2 inhibitors at comparable yield 
and in many cases substantially lower false-hit rate than those of typical VS 
tools reported in the literatures. It is capable of searching large compound 
libraries at sizes comparable to the 13.56M PubChem and 168K MDDR 
compounds at low false-hit rates without the need to define an applicability 
domain, i.e. it has a broad applicability domain that covers the whole chemical 
space defined by the PubChem and MDDR databases. Because of their high 
computing speed and generalization capability for covering highly diverse 
spectrum compounds, Our SVM models can be applied to discover the 
potential leads of c-Src and VEGFR-2 inhibitors for pharmaceutical purposes. 
 
This work on the prediction of multi-target kinase inhibitors pioneers the 
applicaton of SVM based virtual screening. Combinatorial support vector 
machines (C-SVMs) were tested as VS tools for searching dual-inhibitors of 
11 combinations of 9 anticancer kinase targets (EGFR, VEGFR, PDGFR, Src, 
FGFR, Lck, CDK1, CDK2, GSK3). C-SVMs Models were fairly selective in 
misidentifying as dual-inhibitors of the non-dual inhibitors of the same kinase-
pairs and produced low false-hit rates in misidentifying as dual-inhibitors of 
PubChem and MDDR databases. Compared with other methods, 
 Chapter 7 Concluding Remarks 
  165 
Combinatorial SVM VS tools show good capability in identifying dual-
inhibitors of several anticancer target kinase-pairs at comparable and in many 
cases substantially lower false-hit rates. Therefore, C-SVMs models are 
potentially useful to discover multi-target agents for enhancing efficacy and 
reducing counter-target activities and toxicities. 
 
7.2 Limitations and suggestions for future studies 
The SVM models developed using our putative negative dataset are not 
perfect. There are still some false hits that cannot be ruled out easily. These 
false hits are “correctly” identified by our SVM models due to the similar 
structural frameworks with real active compounds. Our molecular descriptors 
used in the SVM model are insufficient to adequately differentiate the 
compounds with similar structural frameworks. Therefore, it is necessary to 
explore different combinations of descriptors and to select any more optimal 
sets of descriptors by using more refined feature selection algorithms and 
parameters in future work. Also it may be helpful to introduce new descriptors 
for more appropriate representations of compounds or descriptors which can 
be used to describe the interaction between proteins and their ligands. 
 
The putative negatives generation method helps a lot in improving the 
performance of SVM based virtual screening. However, a drawback of this 
approach is the possible inclusion of some undiscovered active compounds in 
the “inactive” class, which may affect the capability of ML methods for 
identifying novel active compounds. As will be demonstrated, such an adverse 
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effect is expected to be relatively small for many biological target classes. On 
the other hand, the clustering of chemical space also can affect the generation 
of putative negative dataset. Chemical space clustering is a difficult area in 
cheminformatics. The clustering method, distance metrix selection and 
descriptors are three important factors for clustering. K-means clustering 
method used in this work is not the best clustering method but is suitable and 
computable for large chemical spaces. In future studies, new clustering 
algorithm can be developed for improving the accuracy of chemical space 
clustering. The selection of correlation coefficients and other chemical 
descriptors such as fingerprint also can be the direction of improvement.   
 
The good performance of our SVM based VS system has been showed in 
several projects. However, the good performance of virtual screening is not 
only in screening hits, yield and enrichment factors but also a good potential in 
terms of prediction of novel structure. Experimental studies are necessary to 
do for validating our high performance virtual screening tools. Based on this, 
we have formed extensive collaborations with several research groups on drug 
development. Some compounds are selected and sent to our collaborators for 
further study.  
 
The capability of the combinatorial SVMs in identifying multi-kinase 
inhibitors and other multi-target agents need be further enhanced by 
incorporating knowledge of multi-target agents into VS tool development 
processes. With the discovery of increasing number of selective multi-target 
agents from the current and future drug discovery efforts, it is possible to 
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introduce more comprehensive elements of distinguished structural and 
physicochemical features of selective multi-target agents into the training of 
combinatorial VS tools for more effective identification of selective multi-
target agents. 
 
These years have seen plenty of debate aimed to define which of the many VS 
approaches is the best. However, this question remains with no conclusive 
answer. Each approach has its own advantages and drawbacks, and the choice 
of one or others depends on the particular question faced by the medicinal 
chemist. In terms of performance, ligand based methods tend to present better 
enrichment factors and higher speed serving as a more efficient methodologies 
to remove non active compounds but target based method provides a more 
straightforward picture of interactions between the drug and molecular target 
and a better prediction in terms of novel structures. Now a synergistic, 
rational, synthetic combination of different approaches is a trend. Combined 
VS approach tends to include less costly approaches, usually ligand based VS, 
at the first stage, while the most demanding methods, usually docking, for the 
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